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ABSTRACT 
INFLAMMATION AND PRECLINICAL AD: ASSOCIATIONS BETWEEN 
PERIPHERAL INFLAMMATORY BIOMARKERS, COGNITION, AND AMLYOID-β 
DEPOSITION IN NON-DEMENTED OLDER ADULTS 
 
Lauren E. Oberlin, Ph.D. 
 
University of Pittsburgh, 2019 
 
 
 
 
The central role of inflammatory processes in the development of beta-amyloid (Aβ) pathology 
has been widely shown in rodent models, but has yet to be elucidated in humans, particularly prior 
to the onset of clinical symptoms. We examined associations between peripheral inflammatory 
mediators, cognition, and two neuroimaging Alzheimer’s disease (AD) biomarkers, Aβ plaques 
and hippocampal atrophy, in non-demented older adults. Cross-sectional and longitudinal data 
were used to assess associations between peripheral inflammatory biomarkers (soluble CD14, 
TNF-α receptor concentrations, and IL-6) and memory performance on the California Verbal 
Learning Test (CVLT) and Rey-Osterrieth Complex Figure Test in 173 non-demented older adults. 
Of these 173 participants, 134 were cognitively normal (CN) and 34 had MCI. Ninety of these 
participants underwent repeated assessments at 24 months. Structural MRI and Pittsburgh 
compound B-PET imaging were used to quantify hippocampal volume and Aβ plaque deposition. 
After adjusting for demographics, linear regression analysis revealed that higher levels of TNF-α 
and IL-6 predicted poorer global and verbal memory performance in the full sample, and the CN 
subsample. Elevated concentrations of pro-inflammatory markers were also associated with higher 
global Aβ deposition, specifically among those that also exhibited greater hippocampal atrophy. 
Secondary analysis using template-derived regions of interest showed that these moderation effects 
were specific to PiB uptake in the anterior cingulate gyrus, frontal cortex, and precuneus. These 
associations remained after adjusting for hypertension, diabetes, heart disease and white matter 
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lesions (all p<0.05). Furthermore, higher levels of circulating IL-6 predicted subsequent 
conversion to MCI and increased longitudinal accumulation of Aβ pathology in regions susceptible 
to early amyloid deposition.  Hippocampal volume moderated the association between 
inflammatory markers and Aβ deposition, suggesting potential disease-state-dependent differences 
in peripheral inflammatory profiles during the preclinical phase of AD. These findings highlight 
potential protein signatures that may vary depending on the prodromal phase of disease 
progression, and could help identify those in specific preclinical stages. from CN to MCI. 
Moreover, chronic, low-level systemic inflammation may accelerate the deposition of Aβ 
pathology and, consequently, place individuals at a higher risk of developing clinically significant 
cognitive impairment. 
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1.0 INTRODUCTION 
Alzheimer’s disease (AD) is the 6th leading cause of death in the United States (Association, 2013), 
with nearly 46 million currently suffering from AD or a related dementia worldwide (Dá Mesquita 
et al., 2016). Given the anticipated expansion of the aging population, the number of AD cases is 
expected to reach 100 million by the year 2050 (Brookmeyer, Johnson, Ziegler-Graham, & 
Arrighi, 2007; Gupta & Iadecola, 2015). AD is a progressive brain disorder characterized by early 
impairments in learning and memory, followed by more severe declines in cognition, mood, and 
motor abilities and eventually the inability to complete even simple tasks (Alzheimer's 
Association, 2013Association (2013). These symptoms are preceded by neurodegenerative 
changes that begin at least 10-15 years prior to behavioral symptoms. In fact, one of the 
neuropathological hallmarks of Alzheimer’s disease, amyloid beta (Aβ), is evident in the brain 
more than a decade prior to the onset of memory symptoms (Counts, Ikonomovic, Mercado, Vega, 
& Mufson, 2016; Mortamais et al., 2016; R. Sperling, Mormino, & Johnson, 2014). This extended 
preclinical period likely represents a critical window in which interventions may delay or prevent 
the onset of clinical symptoms. 
At present, AD is incurable. Given the growing health (Brookmeyer et al., 2007; Gupta & 
Iadecola, 2015), psychosocial, and economic burdens (Alzheimer's Association, 2013) associated 
with AD, establishing approaches for slowing or preventing disease development is a public health 
imperative. The purpose of the proposed study is to assess factors that may exacerbate AD 
pathogenesis early in the disease course in order to facilitate early detection of AD and inform 
future efforts to delay or prevent disease progression.  
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Neuroinflammation is one mechanism that may contribute to the pathogenesis of Aβ early 
in the disease course (Canter, Penney, & Tsai, 2016; Heneka et al., 2015). Inflammation in the 
brain is generally an adaptive response to injury in which pro-inflammatory cytokines help reduce 
injury and eliminate destroyed tissue (Dá Mesquita et al., 2016). However, in AD, perturbations 
in the inflammatory response occur, which can exacerbate neural injury and cell death (Bronzuoli, 
Iacomino, Steardo, & Scuderi, 2016; Dá Mesquita et al., 2016) and may perpetuate or accelerate 
Aβ pathology. Evidence of this comes from rodent models in which sustained neuroinflammatory 
processes promote the synthesis and deposition of neurotoxic Aβ species (Decourt, Lahiri, & 
Sabbagh, 2016; Liao, Wang, Cheng, Kuo, & Wolfe, 2004; Sheng et al., 2003). Further, introducing 
an anti-inflammatory agent minimizes Aβ generation and neuronal loss and improves learning and 
memory deficits in rodent and primate models (Decourt et al., 2016; He, Cheng, Staufenbiel, Li, 
& Shen, 2013; Tweedie et al., 2012). While these results implicate neuroinflammation in the 
formation and accumulation of Aβ, translational work in humans is limited by a lack of both 
longitudinal studies and studies conducted during the presymptomatic stage of AD. Consequently, 
the impact of inflammatory processes on the pathogenesis and progression of Aβ early in the 
disease course is not well understood. An enhanced understanding of the mechanisms that 
perpetuate the neurodegenerative processes in AD, particularly prior to the onset of clinical 
symptoms, is imperative to inform the development of targeted interventions aimed at delaying or 
even preventing disease progression. The proposed study aimed to explore the relationship 
between inflammatory factors and preclinical AD pathology, and to assess the contribution of 
peripheral markers of inflammation to the longitudinal progression of Aβ. 
To this end, I leveraged data from an ongoing imaging sub-study of an NIH funded multi-
site placebo-controlled double-blind clinical trial of daily Gingko biloba (Ginkgo Evaluation of 
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Memory Study (GEMS). Following the completion of this multi-site clinical trial in 2008, 173 
non-demented older adults (mean age = 86) from the Pittsburgh site were recruited to participate 
in the GEMS Imaging Sub-Study. All participants completed annual neuropsychological 
assessments. At baseline, 139 participants were cognitively normal and 34 were classified as 
having Mild Cognitive Impairment (MCI)(Lopez et al., 2014). Subjects provided blood samples 
from which serum levels of peripheral inflammatory markers were quantified, including 
concentrations of pro-inflammatory cytokines Interleukin-6 (IL-6), soluble levels of TNF-α 
receptor 1 (TNF-αRI), and TNF-α receptor 2 (TNF-αRII), and cell-surface receptor CD14. Fibrillar 
Aβ plaque deposition was measured in vivo using PiB-Positron Emission Tomography (PET) 
imaging approximately 10 months after the initial blood draw and once again two years later. 
Individuals in the preclinical phase of AD are well represented in this sample, as 48% of this cohort 
exhibited Aβ pathology at baseline, which increased to 75% at follow-up (Hughes, Kuller, et al., 
2014), making this sample uniquely suited to explore both the cross-sectional and longitudinal 
relationships between inflammatory load at baseline and Aβ burden. 
Using these data, I addressed the following aims: 
Aim 1: Assess the relationship between peripheral inflammatory markers and 
cognitive status at baseline.  
H1: Higher concentrations of pro-inflammatory markers will be associated with increased 
risk of meeting clinical criteria for MCI.   
H2: Higher levels of peripheral inflammatory markers will be associated with reduced 
memory performance. A composite measure of memory will be calculated reflecting each 
participants combined performance on visual memory (Rey-Osterrieth Complex Figure Test (R-
O)) and verbal memory (California Verbal Learning Test (CVLT) tasks. 
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Aim 2: Investigate the associations between baseline inflammatory markers and 
fibrillar Aβ deposition, using continuous measures of PiB-PET retention. In addition, assess 
whether the relationship between inflammatory markers and Aβ deposition varies as a 
function of preclinical disease stage.  
H1: Raised levels of inflammatory markers will be associated with elevated global PiB 
retention at baseline.  
H2: The magnitude of the positive association between peripheral inflammatory markers 
and PiB retention will be larger among individuals exhibiting greater neurodegeneration (i.e., 
hippocampal atrophy) at baseline. This relationship will be observed in the combined sample (MCI 
and CN), and in the asymptomatic subsample (e.g., excluding those with MCI).  
Aim 3: Assess the relationship between peripheral inflammatory markers and change 
in cognitive status (i.e., conversion to MCI/dementia) over a two-year period.  
H1: Elevated levels of pro-inflammatory markers at baseline will predict an increased risk 
of conversion to MCI at the 2-year follow-up.  
H2:  Higher concentrations of peripheral inflammatory markers will be associated with a 
decline in memory performance from baseline to follow-up. 
Aim 4: Investigate whether peripheral inflammatory markers predict the progression 
of Aβ deposition over 2 years. 
H1:  Elevated levels of inflammatory markers will be associated with greater Aβ deposition 
at follow-up, as well as increased accumulation of Aβ between baseline and follow-up 
assessments, in the combined sample as well as subjects considered CN at baseline. 
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H2: This relationship will be moderated by preclinical disease stage, such that the positive 
relationship between inflammatory markers and change in Aβ deposition over the 2-year follow-
up will be greater among those that also exhibit neurodegeneration at baseline.  
1.1 BACKGROUND: ALZHEIMER’S DISEASE  
Alois Alzheimer identified the first case of AD in 1901, and over the past century Alzheimer’s 
disease has come to represent one of the greatest public health challenges worldwide. In fact, both 
the World Alzheimer’s Report and the 2013 United States Alzheimer’s Association Report 
indicate that, without the discovery of effective prevention and treatment measures, the number of 
AD cases may increase 2-3 fold by 2050 (Alzheimer's Association, 2010). The current annual cost 
of this disorder is estimated at $203 billion in the United States alone and is expected to grow 
alongside the increased prevalence of AD in the upcoming decades. Despite numerous and varied 
clinical trials, extant medications only provide temporary symptomatic relief for a subset of 
patients (Bronzuoli et al., 2016), and thus, a worldwide effort is currently under way to establish 
treatments to stop, slow, or prevent AD (Bronzuoli et al., 2016). Notably, according to the 
Alzheimer’s Association, developing an intervention that would delay the onset of AD by 5 years 
would result in a 45% reduction in the number of AD cases by 2050 and decrease the estimated 
Medicare costs from $627 billion to $344 billion (Alzheimer's Association, 2010).  
AD is the most common cause of dementia and accounts for an estimated 50-60% of all 
cases of dementia (Association, 2014). While short-term and episodic memory problems are often 
the first cognitive symptoms observed in AD, early signs may vary from person to person and can 
also include visuospatial deficits and difficulties with word-finding (Tarawneh & Holtzman, 
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2012). As the disease progresses, cognitive symptoms worsen and extend to other domains 
including impairments in judgment, reasoning, language, processing speed, and attention. Over 
time, these impairments begin to interfere with the ability to independently complete instrumental 
activities of daily living (e.g., getting dressed, cooking, managing medications and finances). 
Along with cognitive decline, changes in mood and personality, including apathy, aggression, and 
depression, are common in AD. In the final stage of the disease, even simple physical functions 
are impaired and individuals are completely dependent on others for their care. Age is the greatest 
risk factor for AD, as estimates indicate the vast majority of those with AD (82%) are 75 years or 
older (Alzheimer's Association, 2014Association, 2014). Although the duration of illness is 
variable, on average, individuals survive for 4 to 8 years after the initial diagnosis of AD 
(Association, 2013, 2014). Thus, AD is a pervasive, incurable condition characterized by 
progressive changes in cognition, mood, and physical function, that imparts considerable burdens 
on those that it afflicts as well as their loved ones. 
1.2 NEUROPATHOLOGY OF ALZHEIMER’S DISEASE 
Alzheimer’s disease is characterized in the brain by two pathogenic features, extracellular senile 
Aβ plaques and neurofibrillary tangles (NFTs) (Heppner, Ransohoff, & Becher, 2015). Senile 
plaques are comprised of insoluble aggregates of Aβ protein fragments, which form after 
amyloidogenic cleaving of the amyloid precursor protein (APP). NFTs are composed of large 
deposits of hyperphosphorylated tau, a protein that, in a healthy brain, helps to maintain the 
structural integrity of axonal microtubules (Rubio-Perez & Morillas-Ruiz, 2012). A definitive 
diagnosis of AD requires the observation of both fibrillar Aβ plaques and NFTs in post-mortem 
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analysis (Karran, Mercken, & De Strooper, 2011). While it is understood that Aβ plaques and 
NFTs are centrally involved in initiating and promoting the synaptotoxic and neurodegenerative 
changes that underlie the onset and progression of AD, the etiology of AD remains poorly 
understood. In fact, along with Aβ plaques and NFTs, it is now widely recognized that the 
pathogenesis of AD likely involves a complex network of processes involving various cell types 
that interact to provoke a cycle of cellular dysfunction, injury, and death (Musiek & Holtzman, 
2015). However, the particular role of other cellular and molecular process, such as oxidative stress 
and neuroinflammation, that may initiate or exacerbate these hallmark features of AD are not well 
understood.   
The most widely accepted model of AD etiology, known as the amyloid cascade 
hypothesis, suggests that Aβ deposition plays an early and critical role in initiating many complex 
pathologic changes that lead to cell death, synaptic dysfunction, and eventual symptom 
manifestation. Briefly, Aβ peptides result from the aberrant cleavage of the amyloid precursor 
protein (APP). In the non-amyloidogenic pathway (i.e., in a healthy brain), APP is sequentially 
cleaved first by the α-secretase enzyme followed by γ-secretase (Heppner et al., 2015). For reasons 
that are not entirely understood, in the amyloidogenic pathway, APP is initially cleaved by the β-
secretase complex (Canter et al., 2016; Dá Mesquita et al., 2016; Murphy & LeVine III, 2010). 
The subsequent cleavage of APP by γ-secretase generates Aβ peptides of varying lengths, 
including neurotoxic Aβ species (Aβ42), which are prone to aggregation (Heppner et al., 2015; Oh, 
Madison, Villeneuve, Markley, & Jagust, 2013). These go on to form various Aβ aggregation states 
including Aβ oligomers and fibrillar Aβ plaques (Canter et al., 2016; Dá Mesquita et al., 2016; 
Murphy & LeVine III, 2010). Furthermore, two major enzymes largely responsible for the 
clearance of Aβ from the brain, neprilysin and insulin degrading enzyme, are decreased in disease-
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affected regions, so a significant amount of Aβ remains un-degraded (Dá Mesquita et al., 2016; 
Murphy & LeVine III, 2010). Thus, a sequence of molecular processes underlies the formation of 
amyloid plaques, however, a number of questions regarding this pivotal process remain. For 
instance, there is ongoing debate about whether abnormal processing versus dysfunctional 
clearance of Aβ peptides (or a combination of both) represents the primary etiological event in 
sporadic AD (Heppner et al., 2015). Furthermore, the precipitating events that trigger Aβ 
accumulation and the particular factors that exacerbate or accelerate Aβ deposition are poorly 
understood and require further investigation.   
Aβ is largely believed to have an important, causative role in the pathogenesis of AD by 
mediating numerous downstream pathologies that lead to synaptic dysfunction and cell death. In 
a seminal study by Shankar, et al., (2008) Aβ protein oligomers were extracted post-mortem from 
AD brains and introduced into mouse hippocampi (Shankar et al., 2008). Results showed that 
introduction of soluble Aβ oligomers reduced dendritic spine density, inhibited long-term 
potentiation, and facilitated long-term depression. Based on these findings, the authors concluded 
that the pathogenic effects of Aβ in AD include subtle alterations in synaptic structure and function 
(Shankar et al., 2008). Along with directly impacting synaptic processes, Aβ accumulation also 
leads to oxidative damage and impaired regulation of intracellular calcium levels, which can 
impair cellular functioning and lead to cell death (Canter et al., 2016). Furthermore, through 
various processes that are not fully understood, Aβ accumulation and deposition promotes the 
hyperphosporylation of tau proteins (Kantarci et al., 2012) and exacerbates the spread of NFTs 
(Musiek & Holtzman, 2015). Specifically, in vitro and in vivo studies in rodent models indicate 
that, at the molecular level, Aβ may promote tau pathology by stimulating specific tau-targeting 
kinases or by inducing proteases that may modify tau (Musiek & Holtzman, 2015). A recent study 
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also found that Aβ plaques facilitated the spread of NFT’s from the initial site of aggregation in 
the mesial temporal lobe into the broader neocortical areas, and concluded that pathological tau 
formation and transmission requires the Aβ plaque environment (Jacobs et al., 2018). Tau 
hyperphosphorylation results in a number of neurodegenerative changes that lead to symptom 
manifestation, including the disassembly of microtubules, impaired axonal transport, and 
retrograde degeneration and cell death. Thus, Aβ alone does not directly cause all of the pathologic 
changes seen in AD, however, it is critical in the processes of initiating and enhancing numerous 
downstream pathologies that subsequently lead to symptom onset and disease progression. 
1.3 AMYLOID PATHOLOGY AND THE PRECLINICAL PHASE OF AD 
AD is characterized by a protracted preclinical phase, in which neuropathological processes are 
initiated many years, if not several decades, before the onset of clinically detectable cognitive 
symptoms (Racine et al., 2016). Aβ is the earliest detectable pathological change in AD (Jansen et 
al., 2015; R. A. Sperling et al., 2011), with estimates suggesting that Aβ deposition begins 10-20 
years before the expression of cognitive and behavioral symptoms. Thus, the National Institute on 
Aging and the Alzheimer’s Association (NIA-AA) have updated their diagnostic guidelines to 
include three phases of disease progression, the first of which is a preclinical phase in which 
clinical symptoms are absent but the neuropathological processes of AD are underway 
(Association, 2011; Counts et al., 2016). Moreover, within this preclinical stage, the NIA-AA have 
proposed a 3-stage chronological model of neuropathological progression beginning with 1) initial 
Aβ accumulation without contemporaneous neuronal injury, then 2) Aβ pathology and 
downstream changes in the form of neurodegeneration and synaptic dysfunction (e.g., 
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hippocampal atrophy, cellular hypometabolism, tau pathology), followed by 3) amyloidosis, 
neurodegeneration, and the onset of subtle cognitive changes that do not yet meet criteria for MCI 
(Counts et al., 2016; Jack et al., 2011; R. Sperling et al., 2014). Consistent with this model, human 
studies largely show that Aβ aggregation precedes markers of neurodegeneration, tau pathology, 
and cellular hypometabolism, which occur prior to the onset of subtle cognitive deficits (Counts 
et al., 2016). This preclinical staging framework is not intended to be used in clinical settings. 
Instead, the NIA-AA believes this framework will offer researchers the opportunity to identify and 
investigate AD at the earliest possible point, and thereby aid in the development of treatment 
approaches that can be introduced prior to the onset of clinical symptoms (Association, 2011; Jack 
et al., 2011). In sum, Aβ deposits, brain atrophy, and tau pathology are apparent prior to the onset  
of clinically significant cognitive decline, with amyloid pathology representing the first detectable 
neuropathological change in this degenerative cascade.  
The initial preclinical stage of AD is followed by mild cognitive impairment (MCI) (Minor 
Neurocognitive Disorder-DSM-V), which is characterized by noticeable, mild to moderate 
declines in cognitive functioning that exceed normal, age-related changes but do not interfere with 
the ability to function independently in daily life (Association, 2011). The third and final stage of 
disease progression is dementia due to Alzheimer’s disease, which involves a substantial decline 
from a previous level of performance in memory and at least one other cognitive domain that 
impairs independence in everyday activities (Association, 2011). Large-scale pharmaceutical trials 
aimed at slowing or reversing AD have generally been conducted during these latter two stages, 
after cognitive and behavioral symptoms have clinically manifested (Canter et al., 2016; Musiek 
& Holtzman, 2015; R. A. Sperling et al., 2011). Despite the evidence supporting Aβ pathology as 
an early and critical initiator of downstream neurodegenerative changes, trials targeting Aβ have 
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failed to yield clinical improvements or halt further cognitive decline (Canter et al., 2016; R. A. 
Sperling et al., 2011). Even trials that observed reductions in Aβ burden based on biomarker or 
autopsy analysis did not find meaningful clinical improvements (Dá Mesquita et al., 2016). Thus, 
pharmaceutical interventions introduced during this phase of disease development show very little 
benefit. These unsuccessful outcomes have been linked to the fact that cellular dysfunction and 
neurodegenerative changes are well-entrenched by the time cognitive and behavioral symptoms 
are clinically detected. Indeed, studies in cognitively unimpaired older adults have shown that 
diffuse, global Aβ deposition throughout the cortex, as well as high mesial temporal levels of tau 
pathology are apparent prior to the onset of cognitive deficits (Villemange, 2018). In order to delay 
or prevent further neurodegeneration and the onset of clinical symptoms, numerous researchers 
have suggested that the greatest chance for success may lie in targeting these pathological changes 
at the earliest possible moment in the disease course, before Aβ-related downstream changes have 
begun to take place (Dá Mesquita et al., 2016; Musiek & Holtzman, 2015; R. A. Sperling et al., 
2011; R. A. Sperling, Karlawish, & Johnson, 2013). Thus, the preclinical stage of AD represents 
a critical window in which targeting the underlying brain changes early in the disease course may 
delay or prevent the onset of clinical symptoms. However, much remains to be known about the 
pathophysiologic mechanisms that initiate and enhance Aβ accumulation, particularly early in the 
disease course before symptoms have become clinically manifest.  
One of the greatest barriers to understanding, diagnosing, and treating the preclinical phase 
of AD is the absence of observable clinical symptoms. Therefore, the NIA-AA developed a 
working criteria of fluid and imaging biomarkers that can be used to evaluate the presence of AD 
pathology in this critical, asymptomatic phase (Counts et al., 2016; Sharma & Singh, 2016). 
Specifically, Stage 1 of the preclinical phase, characterized as isolated Aβ pathology, can be 
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measured in the cerebrospinal fluid or using PET imaging. The NIA-AA recommends that 
biomarker evidence of neurodegeneration, reflecting Stage 2 of the preclinical phase, be defined 
as either hippocampal atrophy (using Magnetic Resonance Imaging), abnormal cellular 
metabolism (i.e., hypometabolism) on 18F-fluorodeoxyglucose (FDG)-PET, or elevated tau 
pathology. Aβ deposition and tau pathology can also be measured in humans in vivo with PET 
imaging, using radiotracers capable of binding to tau or fibrillar Aβ plaques. [11C]-Pittsburgh 
Compound B (PiB) is a radiotracer that preferentially binds to fibrillar Aβ species and can quantify 
insoluble Aβ deposits in the brain. Standard uptake value ratios (SUVRs) are calculated that 
represent tracer retention, with positive tracer uptake indicative of fibrillar Aβ deposition. Whole 
brain or global amyloid burden is traditionally estimated and dichotomized into Aβ/PiB positive 
(Aβ+) or Aβ/PiB negative (Aβ-) using threshold-based approaches thought to reflect 
pathologically significant levels of Aβ accumulation. Assays for monomers of Aβ measured in the 
CSF can also provide indirect estimates of circulating concentrations of Aβ42 and the ratio of 
Aβ42/Aβ40. Of note, however, CSF-derived estimates of amyloid pathology are limited by a lack 
of regional specificity, as well as observed temporal lags between in vivo detection of Aβ burden 
using PET imaging and CSF-measured Aβ, suggesting a limited ability for CSF to reflect the 
neural environment (Gordon, 2018). This staging framework is illustrated in Figure 1.  
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Figure 1. Staging model of preclinical AD. 
 
The advent of CSF and imaging markers of Aβ have aided in early detection of AD 
pathology, and have allowed researchers to investigate the pathophysiological and cognitive 
correlates of preclinical AD and disease progression. The hypothesized chronology of preclinical 
disease progression, beginning with isolated Aβ accumulation followed by subsequent markers of 
neurodegeneration (hippocampal atrophy, cerebral hypometabolism), has been confirmed using 
these biomarkers in recent longitudinal studies (Jack et al., 2014; Vos et al., 2013). For instance, 
in a large prospective epidemiologic study of preclinical AD, Jack et al., (2014) found that rates 
of amyloid accumulation were independent of baseline hippocampal atrophy, while atrophy rates 
were dependent on the degree of initial amyloid load, with elevated amyloid burden predicting 
accelerated atrophy rates in cognitively normal older adults (Jack et al., 2014). These studies have 
also revealed the regionally-specific evolution of these pathological processes. Specifically, AD-
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related cell death and tau deposition share proximal and temporal specificity, and are initially 
apparent in the medial temporal regions followed by subsequent spreading into the medial and 
lateral regions of the cerebral cortex (Cho et al., 2016; He et al., Villemange et al., 2018). Aβ 
aggregation occurs prior to these degenerative changes, and staging models of early amyloid 
deposition reveal a distinct, regional pattern of pathological accumulation. Although there is some 
variability across studies, Aβ deposits tend to develop first and most substantially in the medial 
frontal cortex and precuneus, then the lateral frontal, inferior temporal, and parietal lobes, followed 
by progression to the occipital and sensory-motor areas, and finally the medial temporal lobe and 
striatum (Cho et al., 2016; (Vlassenko, Benzinger, & Morris, 2012);(Grothe et al., 2017); 
(Villeneuve & Jagust, 2015)).  Thus, the frontal cortex and precuneus are among the regions most 
vulnerable to early amyloid accumulation, with posterior and subcortical structures relatively 
spared until later in the preclinical phase.  
1.4 AMYLOID, COGNITION, AND THE BRAIN 
1.4.1  Aβ pathology in cognitively normal older adults 
Amyloid pathology is not only apparent in individuals with MCI and AD, but also among a 
proportion of older adults clinically considered to be cognitively healthy. Although there is some 
variability across studies in the prevalence of Aβ pathology present in cognitively normal older 
adults, estimates generally suggest that between 20-40% of CN adults aged 60-90 have elevated 
levels of Aβ pathology in the brain (Lim, Maruff, et al., 2013; Oh et al., 2013; R. Sperling et al., 
2014; R. A. Sperling et al., 2011). Of note, the cognitive prognosis for those exhibiting Aβ 
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pathology is worse than those without significant levels of Aβ deposition (Chételat et al., 2013). 
Longitudinal evidence suggests that CN individuals with biomarker evidence of amyloid plaques 
(CSF, blood biomarkers or PET imaging) are 4 times more likely to develop clinically significant 
cognitive impairment/dementia within the subsequent 2-7 years relative to those with little to no 
amyloid pathology (Musiek & Holtzman, 2015). For example, in a longitudinal study of 206 older 
adults (average age ~ 73), Villemagne et al., (2011) found that elevated baseline levels of PiB 
tracer retention were observed in 97% of participants with dementia of the Alzheimer’s type, 69% 
of subjects with MCI, and 31% of healthy controls. Furthermore, 25% of healthy controls with 
elevated PiB uptake at baseline progressed to MCI or dementia of the Alzheimer’s type by 36 
months. In contrast, only one subject in the PiB- group (1.4%) had developed MCI at the time of 
follow-up (Villemagne et al., 2011).  Thus, evidence suggests that the presence of amyloid 
pathology is associated with an increased risk of developing MCI or dementia, although the extent 
to which Aβ predicts the clinical course and subsequent onset of dementia is not well understood. 
In fact, some studies have included participants that manifested the pathological symptoms of AD 
but never expressed clinical symptoms of impairment in their lifetime (R. A. Sperling et al., 2011). 
However, it is unclear whether these participants would have developed clinical symptoms had 
they lived longer (R. A. Sperling et al., 2011). Thus, the presence of Aβ pathology is not yet 
considered a deterministic marker of future AD; however, it is strongly predictive of subsequent 
risk for cognitive decline and disease development.  
Although Aβ burden is associated with future risk of MCI and dementia of the AD type, 
whether Aβ deposition is associated with more subtle deficits in cognitive performance in CN 
older adults remains a matter of debate. Using CSF and brain imaging biomarkers of Aβ burden, 
some studies have observed an inverse association between Aβ pathology and cognitive 
 16 
performance among CN adults (Kantarci et al., 2012; Lim, Ellis, et al., 2013; Petersen et al., 2016; 
Rentz et al., 2010), while other work has failed to detect this relationship (Aizenstein et al., 2008; 
Marchant et al., 2013; Mormino et al., 2014; Storandt, Mintun, Head, & Morris, 2009). In one of 
the largest prospective studies to assess this to date (n = 286 older adults), Petersen et al., (2016) 
found that the 31.7% of cognitively healthy adults exhibiting elevated Aβ levels at baseline 
demonstrated poorer cognitive performance in all domains assessed aside from language, 
including measures of executive function, attention, memory, and visuospatial processing, relative 
to PiB- participants, as well as reduced hippocampal volume and lower glucose metabolism. 
Furthermore, elevated PiB uptake at baseline was associated with an accelerated rate of annual 
cognitive decline in all domains aside from language, as well as a greater annual increase in 
ventricular volume and hippocampal atrophy relative to PiB- subjects (Petersen et al., 2016). These 
results suggest that in CN older adults, elevated Aβ deposition might be associated with subtle 
cognitive deficits in a broad range of cognitive domains as well as regionally specific brain atrophy 
and hypometabolism. To provide a quantitative summary of this literature, a recent meta-analysis 
examined the associations between Aβ burden and cognitive performance across 34 studies, which 
represented data from approximately 3,485 CN older adults (Hedden, Oh, Younger, & Patel, 
2013). Across all studies, Aβ pathology (measured with imaging or fluid biomarkers) was 
significantly associated with reduced performance on measures of episodic memory, executive 
function, and global function while measures of working memory, processing speed, semantic 
memory, and visuospatial function were not associated with Aβ burden (Hedden et al., 2013). In 
sum, a growing body of evidence suggests that Aβ deposition is associated with subclinical 
changes in cognitive function. However, the presence and magnitude of the association between 
Aβ pathology and cognition varies across studies, and the domain specificity of this relationship 
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is poorly understood. The incongruous findings across studies may be attributable to small sample 
sizes, variations in the type and sensitivity of the cognitive measures, the parameters used to define 
CN adults (Insel et al., 2016), and variations in subject demographics and disease progression 
across studies.  
These discrepancies may also be a consequence of the approaches used to estimate and 
quantify amyloid pathology. Specifically, while some studies incorporated continuous measures 
of amyloid pathology, others dichotomized participants into groups of PiB+ and PiB- using 
conventional stratification thresholds. However, recent work suggests that amyloid positivity, 
traditionally defined using global signal thresholds, may correspond to relatively advanced stages 
of preclinical amyloid deposition (Villeneuve et al., 2017; Grothe et al., 2017; Jansen et al., 2018). 
For instance, a recent study in 665 CN participants found that those considered to be in the earliest 
stages of amyloidosis (e.g., regionally distinct tracer retention in the medial frontal, lateral parietal 
and temporal lobes) were classified as amyloid negative using standard binary cutoffs (Grothe et 
al., 2017). Consistent with this, another recent study in 154 CN older adults found that global 
measures of amyloid burden and conventional dichotomization approaches lacked the sensitivity 
to detect regionally restricted amyloid accumulation that occurs in the earliest phases of amyloid 
progression (Villeneuve et al., 2017).  The authors argued that the hierarchical progression of 
amyloid accumulation that takes place in the earliest phases of amyloid pathogenesis may be 
eclipsed, or go undetected, by using global estimates. For instance, a large prospective sample of 
cognitively normal older adults found that elevated levels of Aβ deposition among subjects 
classified as amyloid negative using standard thresholds was associated with poorer cognitive 
trajectories over 4 years (Landea et al., 2018). Furthermore, in a separate sample of CN older adults 
categorized as Aβ- negative using conventional criteria, elevated Aβ deposition significantly 
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predicted subsequent tau deposition in regions associated with AD over the course of 5 years (Leal 
et al., 2018). The authors emphasized the importance of identifying and targeting these populations 
before Aβ is widespread throughout the cortex, and underscored the need for future studies to 
apply less conservative signal thresholds and incorporate continuous measures of global and 
regional PiB retention to better elucidate these relationships. Notably, ROI-based approaches have 
recently been applied to evaluate the relationship between early regional Aβ aggregation and other 
neuropathological markers associated with AD, including tau pathology (Lockhart et al., 2017) 
and hippocampal atrophy (Sone et al., 2017). 
1.4.2  Moderators of the Aβ-cognition relationship 
Genetic, behavioral, and other factors may also moderate the relationship between amyloid burden 
and cognitive function in CN populations. For example, mounting evidence suggests that carriers 
of the APOE ε4 genotype, which represents a major genetic risk factor for sporadic AD, have 
higher rates of Aβ pathology and exhibit accelerated amyloid plaque accumulation relative to 
similarly-aged non-carriers (Petersen et al., 2016). For instance, in a sample of 144 CN older 
adults, Lim and colleagues found that greater cerebral Aβ burden was associated with poorer 
performance on visuospatial and episodic memory tasks. Furthermore, when the sample was 
stratified by APOE status, the relationship between Aβ pathology and cognition was only observed 
in APOE ε4 carriers (Lim, Ellis, et al., 2013). Kantarci et al., (2012) also found that the magnitude 
of the Aβ-cognition relationship was greater among APOE ε4 carriers, even after carriers and non-
carriers were matched on cortical PiB retention (Kantarci et al., 2012). Cognitive reserve may also 
moderate this relationship, as Rentz et al., (2010) found that the inverse relationship between Aβ 
binding and cognition was mitigated among individuals with greater years of education and a 
 19 
higher premorbid verbal IQ (Rentz et al., 2010). Recent work also suggests that higher fitness 
levels are associated with reduced Aβ deposition (B. Brown et al., 2013; Head et al., 2012) and 
may moderate Aβ-related effects on cognition (Schultz et al., 2017). 
Finally, the relationship between Aβ and cognition may also depend on where individuals 
fall on the continuum of preclinical AD (e.g., whether other downstream neurodegenerative 
processes have begun to take place). For instance, Morimono et al., (2014) assessed the 
independent and combined impact of Aβ plaque deposition and neurodegeneration on cognitive 
performance in 166 CN older adults. Fibrillar Aβ deposition was assessed using PiB-PET imaging, 
and neurodegeneration was estimated using measures of hippocampal volume and regionally 
specific hypometabolism using FDG-PET (Mormino et al., 2014). Measures of hypometabolism 
and hippocampal volume were used to approximate different phases of neuropathological changes, 
with subjects exhibiting elevated Aβ and hypometabolism/hippocampal atrophy considered 
further along the preclinical continuum (e.g., phase 2). While Aβ pathology and neurodegeneration 
were independently associated with reduced performance on cognitive tasks, the combination of 
both neurological features was associated with even poorer performance on cognitive tasks and a 
greater magnitude of decline over the course of two years (Mormino et al., 2014). These findings 
are consistent with the staging framework outlined by the NIA-AA, and are supported by recent 
longitudinal work showing that the subsequent appearance of neurodegeneration (i.e., 
hippocampal atrophy, cerebral hypometabolism) following initial Aβ aggregation underlies the 
onset or increases the magnitude of subtle cognitive changes (Jack et al., 2014; Vos et al., 2013 
(Aschenbrenner, Gordon, Benzinger, Morris, & Hassenstab, 2018)). Thus, various factors may 
moderate the relationship between Aβ pathology and cognitive function, including the combined 
presence of neurotoxic Aβ species and downstream neurodegenerative changes. 
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1.4.3  Summary of Aβ, cognition, and AD 
In sum, AD is an increasingly prevalent and incurable form of dementia that is pathologically 
defined by hyperphosphorylated tau tangles and the deposition of fibrillar Aβ plaques. One major 
challenge for treatment is the protracted preclinical phase of AD, in which neurodegenerative 
processes begin many years or several decades before the onset of clinically detectable cognitive 
symptoms (Counts et al., 2016; Mortamais et al., 2016; R. Sperling et al., 2014). The aggregation 
of abnormally cleaved Aβ species commences 10-20 years before clinical symptoms arise, and 
initiates numerous downstream changes that drive the neurodegenerative process in AD. While 
pharmaceutical trials targeting the generation and accumulation of Aβ have shown limited benefit, 
these have almost exclusively been conducted in samples with overt clinical symptoms (MCI or 
AD)(Canter et al., 2016; Dá Mesquita et al., 2016; R. A. Sperling et al., 2011). Targeting AD 
pathology at the earliest possible phase, by minimizing Aβ aggregation and progression, could 
delay or prevent subsequent neurodegeneration and even symptom manifestation.  However, to 
successfully forestall the progression of Aβ pathogenesis, it is imperative to obtain an enhanced 
understanding of the cellular and molecular processes that initiate and exacerbate Aβ early in the 
disease course.  
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1.5 NEUROINFLAMMATION AND AD PATHOGENESIS 
1.5.1  Overview of neuroinflammatory processes under pathological conditions 
Inflammatory processes are initiated early in the course of disease onset, and may play a critical 
role in the pathogenesis and progression of AD. The inflammatory response in the brain is 
important to eliminate the initial cause of cell injury, repair damaged tissue, and remove necrotic 
cells (Calsolaro & Edison, 2016; Rubio-Perez & Morillas-Ruiz, 2012). Neurons, astrocytes, and 
microglia are responsible for the inflammatory reaction in the brain (Rubio-Perez & Morillas-Ruiz, 
2012). Microglia, which comprise 10% of the cells in the central nervous system (CNS), are 
considered the resident macrophages of the CNS as they act as the first line of defense against 
neuronal injury and invading pathogens (Heppner et al., 2015; Walters, Phillips, Zheng, Biju, & 
Kuruvilla, 2016; W.-Y. Wang, Tan, Yu, & Tan, 2015). Under homeostatic conditions, microglia 
act as surveyors, searching for cell damage and pathogens, removing apoptotic neurons and 
helping to maintain synapses (Heneka et al., 2015; Krstic & Knuesel, 2013). Under pathological 
conditions, like brain injury, altered neuronal function, or the detection of pathogens, microglia 
become activated (Heneka et al., 2015; W.-Y. Wang et al., 2015). In order to fight off an 
injury/infection as quickly as possible, activated microglia initiate an immune response and 
interact with astrocytes and neurons to minimize damage to the healthy brain (Heneka et al., 2015; 
Ramesh, MacLean, & Philipp, 2013). Activated microglia have a number of functions including 
phagocytosis, tissue repair, and mediating the production of chemokines, cell adhesion molecules, 
trophic factors and pro and anti-inflammatory cytokines (Heneka et al., 2015; Walters et al., 2016; 
W.-Y. Wang et al., 2015). Cytokines are a diverse class of small proteins that are secreted by 
microglia and astrocytes and act as signaling molecules that help to regulate the duration and 
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intensity of the immune response (Rubio-Perez & Morillas-Ruiz, 2012). Cytokine signaling can 
result in a diverse cascade of events that regulate inflammation and modulate cellular functions, 
including T-cell differentiation, apoptosis, and phagocytosis (Ramesh et al., 2013; Rubio-Perez & 
Morillas-Ruiz, 2012). Cytokines can be pro-inflammatory or anti-inflammatory (i.e., cytokines 
that suppress genes for pro-inflammatory cytokines), and can promote the further activation of 
microglial cells and the production of other cytokines (Rubio-Perez, 2012). Thus, microglia act as 
critical mediators of the immune response in the brain, in part, by initiating the production of 
signaling molecules (cytokines) that help to regulate the inflammatory drive.  
 When an acute injury occurs, this rapid response by the innate immune system is meant to 
be protective, helping to resolve the pathological changes with immediate benefit to the local 
neural environment (Calsolaro & Edison, 2016; Fan, Okello, Brooks, & Edison, 2015; Heneka et 
al., 2015). However, if tissue health is not restored and the pathogenic stimulus persists, a chronic 
state of inflammation unfolds (Calsolaro & Edison, 2016; Heneka et al., 2015; Rubio-Perez & 
Morillas-Ruiz, 2012). Repeated or sustained exposure to inflammatory conditions leads to 
microglial priming, in which the response of microglia to inflammatory signals becomes sensitized 
or exaggerated (Krstic & Knuesel, 2013; Walters et al., 2016). This phenomena is illustrated in 
rodent models, which have shown that chronic or repeated peripheral inflammatory challenge 
primes microglia to remain in an activated state or induce an exaggerated inflammatory response 
in the face of subsequent stimulation (Heneka et al., 2015; Krstic & Knuesel, 2013).This primed 
migroglial phenotype commonly occurs in neurodegenerative conditions and, to a lesser 
magnitude, in healthy aging (Heneka et al., 2015). Microglial priming results in an amplified or 
prolonged inflammatory response, stimulating the further release of pro-inflammatory 
chemokines, cytokines, and reactive oxygen species, which ultimately contributes to and expands 
 23 
cellular dysfunction, neuronal injury and death (Heneka et al., 2015).  Thus, while the response of 
the innate immune system is initially neuroprotective, a phenotypic shift occurs in microglial cells 
in the context of sustained inflammatory conditions that exacerbates the degenerative process.  
1.5.2  Mechanisms linking neuroinflammation and Aβ pathology: evidence from rodent 
and primate models 
Rodent models demonstrate that the early and progressive aggregation of neurotoxic Aβ peptides 
initiates a prolonged inflammatory response that, in turn, exacerbates neural injury and may 
promote disease progression. Pathological changes within all brain tissues are sensed by immune 
cells, including microglia, which are capable of detecting pathogens and significant alterations in 
cellular functioning (Heppner et al., 2015). In murine models of AD, the production of Aβ 
stimulates an innate immune response, beginning with the binding of microglial cells to Aβ species 
via cell-surface receptors, including CD14, CD36, and CD47 (Heneka et al., 2015). Activated 
microglia then stimulate the production of pro-inflammatory chemokines and cytokines, including 
TNF-α, IL-6, and IL-1α, which have numerous downstream effects including further activation of 
microglial cells and phagocytosis (Calsolaro & Edison, 2016; W.-Y. Wang et al., 2015). The 
persistent accumulation of Aβ leads to a primed microglial state (Heneka et al., 2015; Krstic & 
Knuesel, 2013; Walters et al., 2016), typified by an enhanced sensitivity to subsequent 
inflammatory stimuli and a sustained production of pro-inflammatory signaling molecules. 
Consistent with this, a greater concentration of Aβ in transgenic mouse models is associated with 
increased concentrations of pro-inflammatory mediators including TNF-α, IL-1α, and IL-6 
(Heneka et al., 2015; Rubio-Perez & Morillas-Ruiz, 2012). The role of Aβ as a key initiator of the 
inflammatory response in AD is highlighted in a recent rodent study by Balducci and colleagues 
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(2017), which found that a single injection of Aβ oligomers into the lateral ventricle led to the 
rapid activation of glial cells and increased pro-inflammatory cytokine expression (Balducci et al., 
2017). Indeed, disruption of the APP gene, which is a critical precursor to Aβ generation, delays 
and reduces microglial activation (Rubio-Perez & Morillas-Ruiz, 2012). The cellular changes that 
take place in the context of chronic inflammation have numerous downstream effects, including 
the production of reactive oxygen species and nitric oxide synthase, which promote cell 
dysfunction and exacerbate neural injury (Calsolaro & Edison, 2016; Heppner et al., 2015; Rubio-
Perez & Morillas-Ruiz, 2012). Further, while activated microglia may initially promote Aβ 
clearance, hyperactive or primed microglia are less capable of clearing and degrading Aβ 
pathology, creating a cytotoxic environment for surrounding neurons and further promoting the 
aggregation of Aβ plaques (Hickman, Allison, & El Khoury, 2008). Taken together, this evidence 
indicates that, through numerous mechanisms, Aβ species stimulate and perpetuate a heightened 
inflammatory response through microglial priming, which furthers the neurodegenerative process. 
Subsequent studies have sought to determine whether these inflammatory processes are 
epiphenomenal or play a causal role in disease onset and progression. Evidence from rodent and 
primate models indicate a potentially bi-directional relationship between neuroinflammation and 
Aβ such that Aβ aggregates promote pro-inflammatory processes which, in turn, drive the 
accumulation and progression of neurotoxic Aβ species. For instance, reactive astrocytes and pro-
inflammatory cytokines like TNF-α promote the up-regulation of the β-secretase cleaving enzyme, 
which facilitates the formation of toxic Aβ species (Calsolaro & Edison, 2016; Walters et al., 
2016). Furthermore, Aβ pathology appears to increase under inflammatory conditions. In a seminal 
study by Liao et al., (2004), introduction of pro-inflammatory cytokines TNF-α and IL-1β 
increased β-secretase activity and initiated the production of intracellular Aβ. Similarly, using a 
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mouse model in which the precursor protein for Aβ was expressed, Guo (2002) and colleagues 
found that transgenic mice did not develop Aβ deposits under non-inflammatory conditions. 
However, inducing a systemic acute-phase response resulted in Aβ deposition that was preceded 
by an increase in cytokine concentrations in the brain (Guo, Yu, Grass, de Beer, & Kindy, 2002). 
The contribution of pro-inflammatory processes to Aβ progression has also been illustrated in 
rhesus monkeys. Leung et al., (2013) found that microglia isolated from the cortex of aged 
monkeys generated considerable reactive oxygen species when stimulated by fibrillar Aβ. 
Furthermore, delivery of a microglia inhibitory factor abolished fibrillar Aβ toxicity and led to a 
reduction in the volume of damage caused by Aβ (Leung et al., 2011). Similarly, blocking TNF-α 
signaling reduces the presence of Aβ plaques in transgenic mouse models (W.-Y. Wang et al., 
2015). Furthermore, genetic deletion in vitro of microglial cell surface receptors CD26, TLR4, and 
TLR6, which facilitate microglial binding to Aβ species and subsequent activation, reduces 
cytokine production and also prevents the accumulation of Aβ (Heneka et al., 2015). In sum, pro-
inflammatory cytokines, as well as cell-surface receptors that promote a pro-inflammatory 
cascade, enhance Aβ formation and aggregation. Rodent models further suggest that inhibiting the 
inflammatory response may minimize or eradicate Aβ progression (Heneka et al., 2015; Leung et 
al., 2011; E. Wang et al., 2016). These studies indicate a vicious cycle of disease progression in 
which microglial priming results from chronic exposure to Aβ pathology, leading to a sustained 
inflammatory response that exacerbates and heightens Aβ accumulation, thereby furthering the 
pro-inflammatory drive (Calsolaro & Edison, 2016; Heppner et al., 2015; Rubio-Perez & Morillas-
Ruiz, 2012; W.-Y. Wang et al., 2015). 
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1.5.3  Mechanisms linking peripheral immune health to Aβ pathology 
The above studies illustrate the influence of neuroinflammatory signaling on AD-related 
pathology, however, the impact of immune processes is not restricted to cells operating directly in 
the CNS. In fact, several lines of evidence reveal that the peripheral immune environment is 
capable of having neuromodulatory effects. While it was once believed that inflammatory cells in 
the circulation could not invade the CNS, it is now understood that complex, dynamic, and 
elaborate pathways exist that allow for peripheral immune cells to infiltrate the CNS and influence 
inflammatory processes in the brain. These pathways, reviewed by Capuron and Miller (2011), 
include the direct passage of cytokines through permeable regions of the blood brain barrier and 
the active transport of pro-inflammatory cells from the systemic circulation via transport molecules 
located on endothelial cells (Capuron & Miller, 2011). Notably, the pro-inflammatory response of 
brain-resident immune cells to AD pathology facilitates the activate transportation of inflammatory 
mediators from the systemic circulation.  Specifically, Aβ deposits impact immune process by 
interacting with endothelial cells at the blood brain barrier. Indeed, introduction of fibrillary Aβ 42 
has been found to induce the release of inflammatory cytokines from microglial and endothelial 
cells, including TNF-α, IL-6, and IL-1β (Griffin, Kho, Graham, Nicholson, & O’Carroll, 2016; 
W.-Y. Wang et al., 2015). These cytokines impair the integrity of the BBB, causing the BBB to 
become “leaky” and enabling the infiltration of peripheral immune cells including T cells and 
cytokines into the CNS (Heppner, 2015, Rezai-Zadeh 2009; MacPherson et al., 2017(Calsolaro & 
Edison, 2016; W.-Y. Wang et al., 2015). Once in the brain, peripheral cells interact with microglia 
and astrocytes, enhancing microglial priming and leading to the further release of cytokines and 
chemokines (Krstic & Knuesel, 2013; W.-Y. Wang et al., 2015). Moreover, rodent models show 
that prolonged exposure to Aβ deposits also results in the expression of local signaling molecules 
(chemokines) in the CNS, which promote migration of cells from the periphery to the sites of Aβ 
aggregates in the brain (Dá Mesquita et al., 2016; Heneka et al., 2015). Thus, the 
neuroinflammatory response to Aβ deposition includes the expression of signaling molecules and 
pro-inflammatory mediators that modulate the permeability of the BBB and facilitate the migration 
of peripheral immune cells into the brain.  
1.5.3.1 Peripheral immune health and Aβ pathology: evidence from rodent models 
The capacity for the peripheral inflammatory environment to impact the CNS is illustrated by 
murine studies showing how perturbations in the peripheral immune environment lead to 
alterations in inflammatory signaling and Aβ deposition in the brain. For instance, initiating a 
targeted pro-inflammatory response in the periphery in APP transgenic mice has been shown to 
accelerate microglial activation and cytokine signaling in the CNS and increase Aβ plaque 
formation (Heneka et al., 2015; Krstic & Knuesel, 2013). For example, to stimulate a localized 
inflammatory response in the periphery, Kyrkanides and colleagues (2011) induced osteoarthritis 
in the knees and joints of an APP transgenic mouse model of AD. Mice with osteoarthritis 
exhibited elevated mRNA expression of a number of cytokines in the CNS, including IL-1β and 
TNF-α, as well as a greater number of Aβ plaques relative to mice without arthritis. Examining 
these rodent models over multiple time points also revealed that mice with osteoarthritis 
developed Aβ plaques sooner and more rapidly compared to controls, suggesting that an isolated 
systemic inflammatory event leads to an up-regulation of neuroinflammatory processes, and 
promotes and accelerates Aβ pathogenesis (Kyrkanides et al., 2011). Furthermore, MacPherson 
et al., (2017), found that peripheral administration of a TNF-α inhibitor in AD transgenic mice 
resulted  in  decreased   brain  populations  of  both  centrally  and  peripherally  derived  immune 
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cells, including signaling molecules that facilitate the migration of peripheral cells into the CNS. 
Peripheral TNF-α inhibition also resulted in decreased Aβ density and cytokine expression in the 
hippocampus, and protected against deficits in long-term potentiation (MacPherson et al., 2017). 
Thus, peripheral inflammatory cells are capable of penetrating the BBB and reaching the brain, 
where they interact with inflammatory cells in the CNS to exacerbate the inflammatory 
drive and potentiate Aβ pathogenesis.  
1.6 INFLAMMATION AND AD IN HUMANS 
The current body of rodent work provides abundant and strong mechanistic support for the central 
and causal role of inflammatory processes in Aβ pathogenesis. Whether these findings are 
representative of the contribution of systemic inflammatory processes to AD onset and progression 
in humans remains poorly understood. However, studies have sought to address these gaps by 
evaluating the cognitive correlates of inflammatory expression profiles among those with AD, and 
have recently begun to explore the mechanisms underlying this relationship.  
1.6.1  Inflammation, cognitive impairment, and AD 
While the potentially pathogenic role of inflammatory processes in AD remains poorly understood, 
neuroinflammation is now widely recognized as a naturally occurring and predominant feature of 
nearly all neurodegenerative diseases, including AD (Heneka, 2015). The association between 
inflammatory factors and AD in humans was initially identified in post-mortem studies, which 
found that levels of pro-inflammatory cytokines including IL-6, were heightened in the brain tissue 
 29 
of AD patients (Calsolaro & Edison, 2016; Strauss et al., 1992). More recent post-mortem work 
has shown regional co-localization between concentrations of microglia, astrocytes, and Aβ plaque 
deposition in AD, indicating a proximal and potentially functional relationship between Aβ 
pathology and inflammatory mediators (Heppner et al., 2015).  
The correlation between immune processes and AD is further illustrated by studies 
conducted in vivo, which demonstrate heightened CSF and serum/plasma concentrations of pro-
inflammatory cytokines and chemokines in participants with AD compared to CN control subjects. 
This is highlighted by a recent meta-analysis of 175 studies, which found significantly higher 
concentrations of an array of 14 pro-inflammatory cytokines, including IL-6 and TNF-α, among 
subjects with AD relative to CN controls (Lai et al., 2017). Another quantitative synthesis 
demonstrated that heightened concentrations of CRP and IL-6 predicted the subsequent onset of 
all-cause dementia (Darweesh et al., 2018). These patterns have been consistently observed in 
populations with advanced/severe AD (Brosseron et al., 2014). However, studies exploring 
variations in inflammatory profiles between cognitively healthy subjects and those with MCI or 
less advanced AD have yielded contradictory findings. For example, a meta-analysis of 22 studies 
failed to find group differences across a range of inflammatory biomarkers, including 
concentrations of cytokines, chemokines, and cell adhesion molecules, between MCI and CN 
control subjects (Saleem et al., 2015). Results from a large systematic review were in agreement, 
noting that while the majority of studies show elevated levels of pro-inflammatory mediators 
among those with MCI, collectively this body of literature was inconclusive (Brosseron et al., 
2014). Nevertheless, it is unlikely that inflammatory biomarkers are exclusively elevated during 
advanced stages of cognitive impairment given established associations between systemic 
indicators of inflammation and cognitive performance in cognitively healthy populations. For 
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instance, a meta-analysis of prospective longitudinal studies of CN older adults found that elevated 
IL-6 levels predict subsequent cognitive decline, such that those with high baseline concentrations 
of IL-6 were 1.42 times more likely to exhibit global declines in cognitive performance over 
follow-up periods ranging from 2-7 years (Bradburn, Sarginson, & Murgatroyd, 2018). Taken 
together, this data suggests that a heightened inflammatory load is apparent in AD and may also 
be associated with the progression of clinical symptoms. However, as many of these authors note, 
the association between inflammatory markers and cognition in AD remains to be more fully 
elucidated, particularly earlier in the disease course. It is also unclear from this work whether 
inflammatory expression profiles represent a correlate of disease progression or an early 
phenomenon driving neurodegenerative changes.  
These inconsistent findings may be a consequence of study-specific differences in sample 
demographics, biomarker specificity, and diagnostic criteria for MCI and dementia. Also 
underlying these disparate findings in non-demented samples may be disease-state-dependent 
differences in cytokine expression (Swardfager, et al., 2010), as inflammatory processes may play 
a pathological role prior to the onset of cognitive symptoms. Consequently, comparing biomarker 
concentrations between those with and without detectable cognitive impairment naturally 
overlooks those in the preclinical, asymptomatic phase that may already be exhibiting elevations 
in inflammatory signaling. Indeed, in their systematic review, Brosseron and colleagues (2014) 
note that the nature and specificity of cytokine expression may vary depending on the stage of 
disease progression. This is supported by a handful of studies that indicate that biomarkers may 
peak at distinct time points of disease development. For instance, a prospective longitudinal study 
failed to find differences in serum levels of TNF-α between those with AD, MCI, and CN subjects. 
However, those who progressed from MCI to AD exhibited elevated TNF-α concentrations 
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relative to those whose MCI status remained stable over time (e.g., did not progress to AD) (Diniz 
et al., 2010). Relatedly, another longitudinal study by Galimberti (2012) found that participants 
with MCI and mild AD exhibited elevated levels of a chemokine, monocyte chemotactic protein-
1 (MCP-1) relative to controls, while group differences were not observed among those with severe 
AD (Galimberti et al., 2006). Furthermore, MCP-1 levels decreased over the course of the 1-year 
follow-up in the subgroup of subjects with MCI that converted to AD, leading authors to conclude 
that up-regulation of MCP-1 may be an early event in AD that far precedes the onset of clinical 
symptoms (Galimberti, Fenoglio, & Scarpini, 2008). However, the association between 
inflammatory markers and subtle cognitive deficits in the preclinical phase has been infrequently 
explored. Furthermore, whether these biomarkers predict progression to MCI in asymptomatic, at-
risk individuals exhibiting AD-related pathology is not well understood. Determining how these 
associate with AD-related pathology prior to the onset of cognitive symptoms could help identify 
surrogate biomarkers or protein signatures for earlier disease detection and intervention. 
1.6.2  Neuroinflammation and Aβ in humans: neuroimaging 
Mounting evidence in humans indicates that subjects with AD exhibit a distinct pro-inflammatory 
profile that differs from CN controls, although when over the course of disease progression 
differences in biomarker expression begin to manifest remains a matter of debate. To expand upon 
this work and explicate the mechanistic underpinnings of this relationship in humans, recent 
studies have investigated associations between neuroinflammatory processes and AD-related 
pathology, including Aβ. This has been investigated in only a small handful of studies in vivo using 
PET imaging, which have used radiotracers that bind to activated microglia and astrocytes to 
measure inflammatory signaling in the CNS. In a sample of 20 older adults, Santillo et al., (2011) 
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observed higher microglial tracer uptake in the frontal, parietal, and medial temporal lobes among 
AD patients relative to CN controls, as well as a significant correlation between the binding 
potential of microglial tracers and PiB retention among the 9 subjects with AD (Santillo et al., 
2011). This is consistent with findings from Fan et al, (2015), which also observed a correlation 
between the voxelwise distribution of microglial activation and the regional specificity of Aβ 
deposition (Fan et al., 2015). In one of the only studies comparing AD (n = 7), MCI (n = 7), and 
CN (n = 10) populations, Yasuno et al., (2012) found higher microglial uptake in both AD and 
MCI groups relative to CN controls, but failed to find a difference in microglial binding between 
MCI and AD groups. This may be attributable to the small sample size, but may also indicate a 
disease-state-dependent relationship such that microglial activation is enhanced early on in the 
disease course but reaches a plateau as the disease progresses (Yasuno et al., 2012). Notably, 
however, other small-scale studies have failed to detect any group differences in 
microglia/astrocyte activation between AD, MCI, and CN populations (Schuitemaker et al., 2013; 
Wiley et al., 2009).  
These inconsistent findings may, in part, be due to methodological differences and 
measurement limitations across existing studies. Specifically, current microglia tracers are unable 
to isolate particular microglia or identify their specific mode of action (Fan et al., 2015). Given 
that activated microglia can exist in a range of phenotypic states, these tracers are unable to 
discriminate between microglial cells expressing a pro- versus anti-inflammatory phenotype. The 
lack of specificity of this approach limits interpretation, as it is unclear based on these data whether 
increased microglial activation (i.e., greater tracer uptake) reflects a reparative process, a pro-
inflammatory/neurotoxic process, or a combination of protective and destructive processes. 
Therefore, the existing data offers a very circumscribed understanding of the role of the specific 
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cellular components of the inflammatory process in the pathogenesis of AD. Identifying particular 
inflammatory mediators associated with Aβ onset or progression may provide a starting point for 
the development of molecules able to modify specific cellular cascades. Finally, due to the nearly 
exclusive use of cross-sectional designs and the absence of studies conducted in preclinical 
populations, the extent to which inflammatory processes contribute to Aβ progression early in the 
disease course remains unknown.  
1.6.3  Peripheral inflammation and Aβ pathology in humans  
1.6.3.1 Distinguishing fluid biomarkers of immune cell expression 
While the aforementioned studies in humans have employed PET imaging to broadly assess 
microglia/astrocyte activity in the brain, the study described in this thesis examined plasma 
concentrations of 3 specific inflammatory biomarkers: IL-6, TNF-α and CD14. While the use of 
blood-based biomarkers has superior specificity relative to PET imaging in that it is capable of 
detecting levels of particular proteins and cytokines of interest, unlike PET imaging, plasma data 
reflects concentrations of biomarkers in the peripheral circulation. At present, peripheral 
inflammatory markers are not considered to be directly representative of intracerebral 
concentrations (Woodcock & Morganti-Kossmann, 2013). Fluid markers of both amyloid 
pathology and inflammatory concentrations can also be measured in the CSF. Briefly, CSF is 
partly generated from the interstitial fluid of the brain, and because it is not separated from the 
CNS by the BBB, CSF has more contact with the brain than the peripheral circulation. Therefore, 
CSF-derived measures are considered the best obtainable fluid approximation of cellular processes 
in the brain, with blood biomarkers often compared to CSF-based markers to assess how well 
systemic measures correspond with or reflect the neural environment. 
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Currently, the extent to which blood measures of inflammatory markers represent or serve 
as a proxy for inflammatory processes in the CNS in humans is not well understood. One study 
found that plasma concentrations of IL-6 correlated highly with CSF-derived IL-6 levels in patients 
with AD (Sue et al., 2003), which has been shown more recently in healthy populations (Agorastos 
et al., 2014). However, other studies in non-demented samples have failed to find significant 
associations between the expression profiles of inflammatory markers measured in the CSF and 
plasma/serum (Lindqvist et al., 2009; Sasayama et al., 2013; Tsirpanlis et al., 2009). Thus, the 
extent to which peripheral inflammatory signaling captures or represents global inflammatory 
processes versus an independent immune state is not well understood. Nevertheless, the 
neuromodulatory impact of peripheral immune processes has been well established in rodent 
models, and studies in older adults illustrate the salient, and potentially distinct relationship 
between the systemic inflammatory environment and brain and cognitive heath.  
1.6.3.2 Associations between peripheral inflammatory mediators, cognition and brain 
health in non-demented populations 
Evidence of the relationship between the central and peripheral inflammatory environments in 
humans comes, in part, from observational studies showing that conditions or events that are 
restricted to the brain correlate with changes in peripheral cytokine expression (Bradburn et al., 
2018). Specifically, blood levels of pro-inflammatory markers are heightened in multiple sclerosis 
(Macchi et al., 2015) and AD (Swardfager et al., 2010), have been positively associated with 
cerebral microbleeds (Miwa et al., 2011), and are elevated following traumatic brain injury 
(Ramlackhansingh et al., 2011; Woodcock & Morganti-Kossmann, 2013). While interpretation is 
limited by the use of cross-sectional data and the possibility of bidirectional effects (e.g., elevated 
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systemic inflammation may confer greater risk), this does indicate that the peripheral immune 
environment may serve as a biomarker of inflammatory events in the brain.   
Prospective and epidemiological studies in older adult populations also reveal the 
sensitivity of the aging brain to peripheral immune challenge. For instance, heightened 
inflammatory signaling in the circulation following surgical interventions is one of the leading 
mechanisms thought to underlie post-operative cognitive dysfunction, an increasingly understood 
phenomena often observed in older adults that undergo surgeries outside of the CNS. In a meta-
analysis of 54 studies, patients with post-operative cognitive dysfunction and post-operative 
delirium expressed significantly higher peripheral concentrations of two markers of systemic 
inflammation, CRP and IL-6, relative to those that were cognitively healthy following surgery 
(Liu, Yu, & Zhu, 2018). These group differences were not observed pre-operatively, suggesting 
that the systemic inflammatory response to surgical intervention resulted in an up-regulation of 
peripheral immune cells that corresponded to an increased risk of cognitive impairment (Liu et al., 
2018). Furthermore, one small prospective study in 56 individuals with MCI and 25 healthy 
controls found that greater CSF concentrations of TNF-α predicted conversion from MCI to 
dementia over a 9-month period (Tarkowski, Andreasen, Tarkowski, & Blennow, 2003).  
Neuroimaging studies in cognitively healthy older populations provide further evidence of 
the link between systemic inflammation and brain health. For instance, in a sample of cognitively 
healthy older adults, Zhang et al., (2016) found associations between TNF-α and IL-6 and reduced 
grey matter volume in the occipital temporal cortex, bilateral medial PFC, and inferior parietal 
lobule (Zhang et al., 2016). These associations remained even after adjusting for demographic 
factors, APOE ε4, geriatric depression, and cardiovascular risk factors. Plasma/serum measures of 
IL-6 have also been linked with reduced hippocampal volume (Marsland et al., 2015), and another 
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marker of systemic inflammation, CRP, has been associated with cortical thinning in non-
demented older adults (Carlier et al., 2018). Taken together, whether peripheral biomarkers 
provide an indirect or partial representation of the CNS milieu, or capture distinct elements of 
peripheral immune health is not well understood. However, the aforementioned studies in 
cognitively healthy aging populations illustrate the relationship between cytokine signaling in the 
periphery and brain structure and function.  
1.6.3.3 Associations between peripheral inflammation, cognition, and brain health in AD 
The sensitivity of the aging brain to the influence of systemic inflammation may be exacerbated 
in early AD. It is well understand that communication between immune cells in the periphery and 
the CNS is not only possible, but more likely in pathological states, such as during the early 
accumulation of Aβ species. Accordingly, it has been hypothesized that the neuroinflammatory 
response to initial Aβ aggregation (e.g., microglial priming/sensitivity, upregulation of pro-
inflammatory signaling, increased BBB permeability) may make the brain more vulnerable to a 
second immune challenge. This second immune challenge may include an acute event such as an 
infection, as well as chronic systemic inflammation (Eikelenboom et al., 2012; Yasuno et al., 
2017). Consistent with this hypothesis, severe infections in the periphery among those with AD 
have been found to yield cognitive consequences. In a seminal prospective study of 300 older 
adults with AD, acute systemic inflammatory events (defined as a short lived (< 2 months) 
infection or trauma occurring outside of the CNS) were associated with elevated serum levels of 
TNF-α and a 2-fold increase in the rate of cognitive decline over the course of 6 months (Clive 
Holmes et al., 2009). Conversely, those who had low serum TNF-α levels throughout the study 
exhibited no cognitive decline over the course of 6-months. Thus, inflammatory events that 
occurred in the periphery resulted in heightened TNF-α levels and predicted a more rapid rate of 
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cognitive decline. These findings are consistent with this two-step hypothesis, which suggests that 
early Aβ aggregation results in a neuroinflammatory cascade that facilitates the ability for 
peripheral cells to infiltrate the CNS and enhances the influence of these immune cells on Aβ 
deposition. Along with acute illness, rodent models indicate that the systemic inflammatory 
environment may also act as a contributing factor towards further neuroinflammatory signaling 
and Aβ pathogenesis. 
 In humans, the role of the peripheral pro-inflammatory drive in AD onset is supported by 
mounting evidence showing that cardiovascular disease (CVD) risk factors that result in a 
sustained, pro-inflammatory state represent well-known risk factors for AD. Specifically, 
hypertension, midlife obesity, insulin resistance, and high cholesterol, all of which correlate with 
chronic, low-grade inflammation, are predictors of late-life AD ((Barnes & Yaffe, 2011; Calsolaro 
& Edison, 2016; Kivipelto et al., 2001; Kivipelto et al., 2005; Rethorst, Bernstein, & Trivedi, 2014; 
Srikanthan, Feyh, Visweshwar, Shapiro, & Sodhi, 2016; Welty, Alfaddagh, & Elajami, 2016; 
Whitmer, Sidney, Selby, Johnston, & Yaffe, 2005; Zammit, Katz, Derby, Bitzer, & Lipton, 2015). 
Notably, emerging work has also demonstrated a relationship between CVD risk factors and AD-
related neuropathology. A series of recent studies have revealed associations between PET-derived 
measures of Aβ burden and genetic markers of cholesterol transport (Hughes, Lopez, et al., 2014), 
high blood pressure (Hughes, Lopez, et al., 2014), overweight/obesity (Glodzik et al., 2016), and 
elevated triglycerides (Choi et al., 2016). Using the GEMS sample of non-demented older adults, 
arterial stiffness, a proxy for atherosclerosis, was recently found to predict the progression of Aβ 
pathology over the course of two years (Hughes, Kuller, et al., 2014). A recent, population-based 
prospective study also demonstrated the cumulative effect of multiple cardiovascular risk factors 
on subsequent Aβ burden 20 years later (mean age at follow-up = 73) (Gottessman et al., 2017). 
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Thus, while the mechanisms linking CVD risk factors to AD risk and Aβ burden are not fully 
understood, systemic inflammation has been identified as one probable pathway underlying these 
associations. Specifically, the early deposition of Aβ may represent an initial inflammatory event 
that permits pro-inflammatory cells that proliferate in a state of chronic inflammation to have 
additive or even distinct neuromodulatory effects. 
1.6.4  Circulating inflammatory biomarkers and AD-related pathology 
To date, very few studies have evaluated the associations between CSF and blood indicators of 
inflammatory biomarkers and AD-related pathology. Magalhães and colleagues (2018) explored 
associations between systemic inflammatory markers, CSF-derived estimates of AD-related 
proteins (Aβ and tau), hippocampal volume and functional connectivity among CN older adults 
and those with amnestic MCI and mild AD. They failed to find associations between inflammatory 
biomarkers and CSF-measured Aβ42. However, relative to cognitively healthy controls, individuals 
with amnestic MCI and mild AD exhibited elevated levels of serum cytokines TNF-α, IL-10, and 
IL-12, which corresponded to decreased functional connectivity in the default mode network, 
which is commonly disrupted in AD (Magalhães et al., 2018). Given that similar trends were 
observed in subjects with dementia and amnestic MCI, the authors concluded that systemic 
inflammation may correlate with functional connectivity disruption, even early in disease 
progression. Using a panel of 11 inflammatory and vascular biomarkers measured in the CSF, 
Janelidze et al., (2018) explored whether inflammatory mediators correlated with disease phase. 
Participants were categorized into preclinical (Aβ+), prodromal (Aβ+/MCI) or dementia groups 
based on neuropsychological data and CSF-derived estimates of Aβ and tau pathology. They found 
that cell adhesion molecules, but not CSF inflammatory cytokines (e.g., IL-6, IL-7, IL-10), were 
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elevated among those in the preclinical, prodromal, and dementia stages (Janelidze et al., 2018). 
Conversely, D’Anna et al., 2018 measured plasma levels of IL-6 and IL-10 in 18 CN patients and 
27 with AD, and found that both pro-inflammatory biomarkers were associated with CSF-
measured Aβ42 among those with AD (D'Anna et al., 2017). Taken together, this circumscribed 
body of literature suggests potential associations between inflammatory mediators and AD-related 
pathology. However, the current work is limited by the use of small sample sizes, populations with 
symptomatic AD, and a reliance on CSF measures of inflammatory markers and Aβ pathology. Of 
note, CSF-based Aβ estimates may not be detectable until Aβ accumulation has reached global 
levels in the brain, making it harder to identify biomarkers that may be most temporally relevant 
or may peak at earlier phases of disease onset.  
In fact, markers of systemic inflammation may represent independent immune processes 
in the periphery and provide information that is distinct from CSF-based immune measures. For 
instance, a recent meta-analysis of 54 studies assessed differences in blood and CSF obtained 
cytokine concentrations among individuals with AD relative to CN controls. Pooled estimates 
across 40 studies measuring peripheral cytokine levels showed that concentrations of pro-
inflammatory cytokines including IL-6, TNF-α, TGF, IL-1, IL-12, and IL-18 were elevated in AD 
participants compared to cognitively healthy controls, while no group differences were observed 
in concentrations of interferon gamma (INF-γ), anti-inflammatory cytokines IL-4 or IL-10, pro-
inflammatory cytokine IL-8, or C-reactive protein (CRP). Interestingly, among the 14 studies that 
measured cytokine concentrations in the CSF, there was not a significant difference in IL-6 or 
TNF-α between cognitively healthy and AD participants (Swardfager et al., 2010). These findings 
not only demonstrate the potential biomarker specificity of this relationship, they also suggest that 
inflammatory markers derived from the circulation may capture information that is unique from 
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that measured in the CSF. In the context of amyloid pathology, a recent study evaluated whether 
CSF and plasma measures independently predicted markers of AD pathology in a sample of non-
demented middle-aged and older adults with a family history of AD. Bettcher and colleagues 
(2018) found that plasma concentrations of pro-inflammatory cytokine IL-8 were positively 
associated with CSF levels of amyloid burden (sAAPβ), while measures of the same biomarker 
obtained in the CSF showed no association with amyloid load (Bettcher et al., 2018). Furthermore, 
the relationship between plasma IL-8 and sAAPβ remained after adjusting for CSF IL-8, 
suggesting a potentially distinct pathway linking peripheral inflammation to amyloid pathology. 
Taken together, although these results require further exploration, they indicate that circulating 
inflammatory biomarkers may be uniquely or independently associated with brain structure and 
function in AD.  
Only one study, to our knowledge, has examined the association between peripheral 
immune signaling and amyloid burden in vivo using PET imaging. Specifically, in a sample of 36 
cognitively normal older adults aged 55-85, Yasuno and colleagues (2017) collected peripheral 
concentrations of a number of lymphocytes including B cells (CD19+, regulatory T cells (CD4+, 
FOXP3 +, CD25+), and cytotoxic T cells (CD8+ and CD3+). Subjects were categorized into low 
and high PiB-PET groups based on the global cortical mean signal uptake using conventional 
thresholds.  They found the percentage of cytotoxic T cells (CD3+ and CD8+) to be significantly 
greater among subjects in the high PiB group relative to those in the low PiB group after controlling 
for age, gender, and education level. Including global PiB retention as a continuous variable 
revealed that the percentage of cytotoxic T cells in the periphery explained 17% of the variance in 
global amyloid burden, after adjusting for demographic factors. Given that this study was 
conducted in a non-demented sample, the authors concluded that peripheral immune changes start 
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early in disease onset, prior to the manifestation of cognitive deficits. They also note that these 
results lend support to the notion that inflammatory processes in the brain of individuals with Aβ 
pathology may have systemic parallels (Yasuno et al., 2017).  
1.6.5  Anti-inflammatory treatments and AD 
Given the compelling link between inflammation and AD pathogenesis, anti-inflammatory agents 
including NSAIDs and glucocorticoid steroids have been considered as treatment options for AD. 
Rodent models have shown that treatment of mice that overexpress APP with an anti-inflammatory 
agent (Ibuprofen) reduces microglial activation and the accumulation of Aβ plaques in the cortex 
(Yan et al., 2003). Furthermore, upon exposure to TNF-α, neurons that were pretreated with 
ibuprofen showed reduced production of Aβ relative to untreated neurons (Rubio-Perez & 
Morillas-Ruiz, 2012). The potentially protective effects of anti-inflammatory agents in humans 
were initially observed in epidemiological studies of populations with osteoarthritis or rheumatoid 
arthritis, who are conventionally treated with anti-inflammatory drugs such as NSAIDs for long 
periods of time. These findings, along with subsequent cross-sectional research, confirmed an 
inverse relationship between treatment with NSAIDS for conditions like arthritis and the incidence 
of AD (Heneka et al., 2015; Walters et al., 2016). In addition, a prospective, observational study 
found a reduction in AD risk among subjects who had regularly taken NSAIDs for at least 24 
months (In'T Veld et al., 2001; Rubio-Perez & Morillas-Ruiz, 2012). While findings from animal 
models and observational epidemiological studies have shown promise, randomized, placebo-
controlled, double-blind trials of anti-inflammatory treatments for AD have had little success 
(Heneka et al., 2015; Rubio-Perez & Morillas-Ruiz, 2012; Walters et al., 2016). Specifically, 
administration of NSAIDS for 8-16 months had no effect on the rate of cognitive decline or disease 
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progression in individuals with AD (Heneka et al., 2015).  Similar to pharmaceutical trials 
targeting Aβ, disease-modifying interventions using anti-inflammatory agents have been largely 
conducted in populations with MCI or AD, and thus the timing of treatment initiation may be 
critical. Despite this, the temporal relationship between inflammatory processes and 
neuropathological progression, particularly during the preclinical stage of AD, has been 
remarkably understudied. In order to sufficiently clarify the role of inflammatory factors in AD, 
longitudinal studies in humans are necessary to disentangle the complex functions of these 
processes early in the course of disease onset. 
1.6.6  Summary of existing literature 
The aggregation of neurotoxic Aβ species is an early and critical event in the pathogenesis of AD, 
contributing to a cascade of neuropathological changes that result in synaptic and neural 
dysfunction, cell death, and eventual symptom manifestation. However, pharmaceutical trials 
targeting the generation and deposition of Aβ in populations with MCI or AD have been largely 
unsuccessful. Targeting Aβ earlier in the disease course, before downstream neurodegenerative 
changes have taken place, may be the most promising approach to modify disease progression. As 
described by Sperling et al., (2011), “it is possible that similar to cardiac disease and cancer 
treatment, AD would be optimally treated before significant cognitive impairment, in the 
presymptomatic or preclinical stages of AD” (R. A. Sperling et al., 2011). In order to effectively 
target Aβ, a thorough understanding of the mechanisms that perpetuate this pathogenic process is 
necessary, although currently, these are poorly understood.  
Inflammatory processes may have a central and causal role in the pathogenesis of AD, as 
evidenced by numerous rodent and primate models. According to these studies, Aβ aggregation 
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initiates a prolonged inflammatory response, resulting in a cascade of events that exacerbates tissue 
damage and neurotoxicity, and may also promote the generation and progression of Aβ pathology. 
Administration of anti-inflammatory agents reduces Aβ burden in transgenic mouse models, and 
observational, population-based studies indicate that long-term use of NSAID’s is associated with 
a reduced incidence of AD onset. However, randomized placebo-controlled pharmaceutical trials 
in AD populations have failed to generate clinical improvements or delay symptom progression. 
The preclinical phase may be an optimal time to initiate a therapeutic intervention, however, the 
implementation of such trials are hampered by a circumscribed understanding of the relationship 
between inflammatory factors and AD pathology early in the disease course. This is further 
complicated by the fact that the inflammatory cascade, at least initially, may involve a combination 
of neuroprotective and neurotoxic functions. Extant work in humans is limited by 1) the use of 
small sample sizes, 2) methodological approaches that are unable to differentiate between pro- and 
anti-inflammatory processes in activated cells 3) focused only on samples with clinically 
detectable cognitive impairment, and 4) have almost exclusively involved cross-sectional designs.  
1.7 PRESENT STUDY 
The present study aims to address these gaps in the literature by using a large sample of non-
demented older adults with measures of specific peripheral inflammatory biomarkers and PiB-PET 
measures of Aβ deposition with longitudinal follow-up. Gaining a better understanding of the 
association between specific inflammatory biomarkers and the deposition and progression of Aβ 
plaques in preclinical AD will offer insight into whether regulating particular cells may modify 
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disease progression, and thus could inform the development of preventative treatments and help 
identify the optimal time to initiate targeted interventions.   
We hypothesized that elevated concentrations of circulating pro-inflammatory biomarkers 
would be associated with poorer memory performance and greater global amyloid deposition at 
baseline. Given our use of an entirely non-demented sample, we further hypothesized that these 
biomarkers would predict amyloid burden specifically in brain regions susceptible to early Aβ 
deposition, including the anterior cingulate gyrus, lateral frontal cortex, and the precuneus. Given 
the plasticity of the microglial phenotype and the sensitivity of these cells to sustained 
inflammatory stimuli and early Aβ accumulation, it is possible that the influence of particular 
inflammatory mediators on Aβ deposition may vary as a function of disease phase. We used a 
theoretically driven approach to assess potential disease-state-dependent differences based on two 
converging bodies of literature: 1) rodent models indicating alterations in the inflammatory 
response to early Aβ species which, in turn, promotes Aβ pathogenesis and 2) the temporal 
sequencing of neuropathological changes in preclinical AD. Therefore, consistent with the 
preclinical staging framework outlined by the NIA-AA, hippocampal atrophy was used in the 
present study as a biomarker of neuropathological progression. By including hippocampal volume 
as a moderator, we sought to estimate preclinical disease phase by identifying those that may be 
exhibiting downstream neurodegenerative changes (corresponding to phase 2 of the preclinical 
staging framework). While there are limitations to this approach, which are elaborated on in the 
discussion, hippocampal volume has frequently been used in cross-sectional and longitudinal 
studies to distinguish individuals representing more advanced stages of preclinical disease 
progression. We hypothesized that the association between pro-inflammatory signaling and 
amyloid deposition would be greater in magnitude among those further along the preclinical 
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continuum (e.g., those exhibiting downstream neurodegenerative changes). Finally, we anticipated 
that elevated levels of systemic inflammatory mediators would predict cognitive decline and 
progression of amyloid pathology over the 2-year follow-up period.  
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2.0 METHODS 
2.1 PARTICIPANTS 
Participants were recruited from a multisite, double-masked, placebo controlled randomized 
clinical trial of daily use of Ginkgo biloba (GEMS trial) (Mathis et al., 2013). The GEMS study 
began in September 2000 and concluded with a final closeout visit between October 2007 and 
March 2008 (Hughes, Kuller, et al., 2014; Hughes, Lopez, et al., 2014; Lopez et al., 2014). The 
trial involved 3,069 community dwelling older adults aged 72 to 96 years at baseline, including 
966 participants at the University of Pittsburgh site. The primary aim of the study was to assess 
whether daily use of 240 milligrams of Gingko biloba would reduce the incidence of all-cause 
dementia. Results indicated that daily Gingko biloba use did not slow or delay the development of 
dementia, and did not result in less cognitive decline in CN subjects or those with MCI (Snitz et 
al., 2009). A subsample of 194 non-demented subjects from the Pittsburgh site were subsequently 
recruited to participate in the GEMS Imaging Sub-Study, which is an ongoing longitudinal 
observational study involving annual or biannual visits that include neuroimaging and cognitive 
assessments. 
Participants for the original GEMS study were recruited from 4 US communities including 
Sacramento, California (University of California-Davis), Winston-Salem and Greensboro, North 
Carolina (Wake Forest University), Pittsburgh, Pennsylvania (University of Pittsburgh), and 
Hagerstown, Maryland (Johns Hopkins University). Participants were recruited using voter 
registration and other purchased mailing lists (DeKosky et al., 2008). 
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2.1.1  Exclusionary criteria 
Exclusionary criteria for the GEMS clinical trial included 1) baseline dementia 2) use of the 
anticoagulant warfarin 3) use of tricyclic antidepressants, antipsychotics, cholinesterase inhibitors, 
or other medications with psychotropic or cholinergic effects, 4) daily use of 400-IU of vitamin E, 
5) electroconvulsive therapy within the past 10 years or hospitalization for depression within the 
past year, 6) history of bleeding disorders, 7) history of Parkinson’s disease, 8) abnormal thyroid 
(serum creatine > 2.0 mg/d) or liver function tests at initial assessment, 9) hematocrit level < 30%, 
10) low baseline vitamin B12 levels (< 210 pg/mL), 11) platelet count < 100 X 103/μ L, 12) an 
unwillingness to discontinue taking over-the-counter Ginkgo biloba, or 13) a disease-related life 
expectancy of < 5 years (DeKosky et al., 2008; Snitz et al., 2009). Exclusionary criteria for the 
subsequent GEMS Imaging Sub-Study include dementia at the GEMS closeout visit (in 2008) or 
contraindications for neuroimaging (Mathis et al., 2013). 
2.2 PROCEDURE 
In the GEMS clinical trial (2000-2008), participants were randomized to receive either 240 mg 
daily of Gingko biloba extract or a placebo (median follow-up of 6.1 years) (DeKosky et al., 2008; 
Snitz et al., 2009). For the purposes of the present study, only data acquired at the final GEMS 
visit is relevant and therefore detailed here. Participants returned for a final GEMS closeout visit 
between October 2007 and March 2008. At this time, participants completed a neuropsychological 
assessment and resting blood pressure, height and weight data, and a blood draw were obtained 
(Hughes, Lopez, et al., 2014). Approximately 10 months after the GEMS closeout visit, the 194 
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participants that were recruited into the GEMS Imaging Sub-Study completed a 
neuropsychological assessment. Neuroimaging measures were also taken at this time, including 
brain MRI and PET using the Aβ radiotracer PiB. Two years later, in 2011, 183 participants 
returned for follow-up cognitive assessments and 103 underwent neuroimaging, including both 
MRI and PiB-PET imaging. Other studies using this dataset have found that participants in the 
GEMS Imaging Sub-Study were slightly younger than the full sample of 671 participants at the 
Pittsburgh site that completed the original GEMS protocol (84.0 [SD 2.8] versus 84.4 [SD 3]), but 
otherwise these samples did not differ in terms of gender, ethnicity, education, estimated 
premorbid intelligence, or APOE ε4 status (Mathis et al., 2013; Snitz et al., 2013). The 103 subjects 
in the GEMS Imaging Sub-Study that returned for follow-up imaging assessments in 2011 did not 
differ from the baseline sample of 183 subjects with respect to age, gender, APOE ε4 status, 
cognitive status in 2009 or body mass index (Hughes, Kuller, et al., 2014). The GEMS clinical 
trial and the GEMS Imaging Sub-Study were approved by the institutional review board and 
required participants to complete informed consent prior to any study procedures (Hughes, Kuller, 
et al., 2014; Lopez et al., 2014). The study timeline for the GEMS trial and the following GEMS 
Imaging Sub-Study can be found in Figure 2.  
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Figure 2. GEMS study timeline. 
2.3 IMAGINE ACQUISITION AND PREPROCESSING 
2.3.1  Magnetic Resonance Imaging 
MRI data were collected using a GE Signa 1.5 T scanner and a standard head coil (Price et al., 
2005). A high-resolution T1-weighted volumetric spoiled gradient recalled sequence (SPGR) was 
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acquired (0.937 X 0.937mm) in either the sagittal or coronal orientation with the following 
parameters: TE/TR = 5/25; flip angle = 40 degrees; slice thickness = 1.2mm/0mm interslice (Price 
et al., 2005). 
The high-resolution structural data obtained from the MR sequence was used to estimate 
hippocampal volume. Specifically, hippocampal volume was calculated for each subject and 
normalized to each participants total intracranial volume (ICV). An automated approach was used 
to estimate total ICV, which reflects the volume within the “inner skull” and was computed using 
FMRIB’s Brain Extraction Tool (Lopez et al., 2014). Hippocampal volume was calculated using 
an atlas-based segmentation approach. Hippocampal ROIs were defined using a reference brain 
(MNI) and normalized to fit each participant’s anatomical image (Lopez et al., 2014). A ratio of 
total bilateral hippocampal volume relative to total ICV was calculated and multiplied by 100, 
which was used as a continuous estimate of hippocampal atrophy/neurodegeneration in statistical 
models. To create a binary variable indicative of neurodegeneration, a W-score was also 
calculated. This is a commonly used approach to assess and classify hippocampal atrophy that is 
consistent with an AD profile (Jack et al., 2008; Knopman et al., 2012; Prestia et al., 2013; Wirth 
et al., 2013). In the present study, a W-score was calculated based on the normal distribution of an 
independent reference group of CN older adults (n = 77; age range = 45-89). In this reference 
group, hippocampal volume was regressed onto age, gender, and total ICV, yielding residuals that 
were converted to percentiles and subsequently standardized (i.e., converted to z-scores). The 
upper and lower tails of this normal distribution were used to identify values that represent the 
highest and lowest hippocampal volumes within the CN reference sample. From this, a W-score 
was derived that accurately predicted AD diagnosis with 85% sensitivity in a second independent 
sample of 51 individuals with AD (W-score: < -0.9063) (Snitz et al., in press). In other words, W-
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scores can be considered age, gender, and ICV adjusted Z-scores, and therefore negative W-scores 
represent adjusted volumes below the expected mean for the CN reference sample (Jack et al., 
2008). Thus, in the proposed study, neurodegeneration was included as a moderator and was 
represented using a binary variable that reflected subjects that do not reach the pre-identified 
threshold (ND-) and those that reach or exceed an ICV-adjusted W-score of -0.9063 (ND+). 
2.3.2  Positron Emission Tomography 
PET imaging data was collected following the MRI sequence. Using a Siemens/CTI ECAT HR+ 
scanner, PiB-PET data acquisition began 50 minutes after participants were injected with 15 +- 
1.5 mCi of PiB in 3-dimensional imaging mode (2.4 mm slice width, 63 planes)(Lopez et al., 2014; 
Snitz et al., 2013). PET data were reconstructed using filtered back-projection, with a final PET 
image resolution of ~6 mm (transverse and axial) (Lopez et al., 2014; Mathis et al., 2013; Snitz et 
al., 2013). PiB retention was scaled to the injected dose and body mass of each participant to yield 
standardized uptake values (SUV) (Snitz et al., 2013). An SUV ratio (SUVR) was calculated using 
PiB uptake in the grey matter tissue of the cerebellum as a reference region (Snitz et al., 2013). 
The cerebellum is a commonly used reference region when assessing amyloid binding, as Aβ 
plaque accumulation is typically negligible in the cerebellum. 
Following PiB-PET data acquisition, PET images were co-registered to MR images to 
facilitate region of interest (ROI) segmentation. The SUVRs within 6 bilateral ROI’s (anterior 
cingulate, anterior ventral striatum, frontal lobe, lateral temporal cortex, precuneus, and parietal 
cortex) were averaged to reflect a global estimate of PiB retention (mean SUVR) (Lopez et al., 
2014). This continuous variable served as the primary dependent variable in statistical models 
investigating patterns of Aβ plaque deposition.  
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There are two methods of delineating the aforementioned ROI’s, which include a manual 
approach and an automated approach using established software and template image. Both manual 
and automated approaches are commonly used and results of these approaches are highly 
correlated, however, at the time of data collection in 2011, manual segmentation was considered 
the most precise method (Rosario et al., 2011). Each approach was employed in the present study, 
with manual segmentation applied in the subjects with longitudinal data and automated 
segmentation used in the full baseline sample. Inter-rater reliability of manual tracing obtained 
across 3 raters demonstrates substantial reliability (intraclass correlation coefficient ≥ 0.932) 
(Rosario et al., 2011).  
Automated approaches are often used for efficiency purposes, particularly in studies with 
large sample sizes, as manual segmentation is quite labor intensive (Rosario et al., 2011). In the 
present study, the baseline PET data (n = 194) collected in 2009 was processed using an automated 
segmentation approach. Specifically, ROI’s were manually drawn on a high-resolution MR image 
of a female older adult (79 years) with MCI (Mathis et al., 2013; Snitz et al., 2013). This was 
intentionally chosen as the template image as it represented a moderate degree of brain atrophy 
(Jagust et al., 2010). Using Statistical Parametric Mapping (SPM8) software, each subjects PET 
and MRI data were co-registered, and the MR image was subsequently normalized to the MCI 
template (Rosario et al., 2011). The parameters used to normalize the high-resolution MR image 
to the MCI template were then applied to each subject’s PET data, resulting in spatial 
normalization of the PET data to the MCI template (Rosario et al., 2011). The ROI’s drawn on the 
template image were then applied to each subjects normalized PET image, generating SUVR 
estimates for each ROI (Jagust et al., 2010; Rosario et al., 2011). This yielded 10 distinct ROI’s 
from which PiB retention in the grey matter tissue was estimated, including the anterior cingulate 
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gyrus, frontal cortex, precuneus, anterior ventral striatum, lateral temporal cortex, mesial temporal 
cortex, occipital cortex, occipital pole, sensory-motor cortex, and parietal lobe.  
In the 103 subjects that underwent PET imaging at baseline and follow-up, a manual ROI 
delineation approach was employed. Using this method, each participants MR and PET data were 
co-registered, and each subject’s native MR space was used to generate the ROIs. Thus, manual 
ROIs were hand drawn using various anatomical criteria by trained raters, based on each individual 
subjects structural MR images. Co-registration of the MR and PET images allowed these manually 
drawn ROI’s to be applied to the PET data, from which continuous SUVR estimates in each ROI 
were obtained (Rosario et al., 2011). The manual approach resulted in 16 bilateral ROIs including 
the anterior cingulate gyrus, anterior ventral striatum, dorsal frontal cortex, frontal cortex, lateral 
temporal cortex, mesial temporal cortex, occipital cortex, occipital pole, pregenual anterior 
cingulate, parietal cortex, global precuneus and precuneual divisions (lower precuneus, middle 
precuneus, and upper precuneus), ventral frontal cortex, and sensory-motor cortex. A measure of 
global PiB retention reflects the average signal across the anterior cingulate, frontal cortex, lateral 
temporal cortex, parietal, precuneus and anterior striatum ROIs. In all models, continuous 
estimates of PiB retention were used as dependent variables in order to maximize power and 
explore global and regional associations that may not be captured using conventional threshold-
based classification methods (Grothe et al., 2017; Jansen et al., 2018; Villeneuve et al., 2015).  
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2.4 MEASURES 
2.4.1  Neuropsychological assessments 
Participants in the GEMS Neuroimaging Sub-Study completed annual neuropsychological 
assessments, beginning in 2009. The neuropsychological evaluation included the Mini-Mental 
State Examination (MMSE), as well as measures of memory, (California Verbal Learning Test, 
Rey-Osterrieth Figure Test), language (semantic (animals) and phonemic fluency (FAS)), 
processing speed (Trail Making Test, Part A), and executive function (Trail Making Test, Part B) 
(Snitz et al., 2013). This battery was subsequently administered again at the two-year follow-up 
(in 2011), and at both baseline and follow-up, these assessments were completed within 6 weeks 
of neuroimaging acquisition. Cognitive adjudication was completed by the GEMS Cognitive 
Diagnostic Center, which took into consideration historical serial cognitive assessments obtained 
during the course of the GEMS trial, but were blinded to the baseline and follow-up neuroimaging 
results (Mathis et al., 2013; Snitz et al., 2013). Performance on 1 to 3 cognitive tests that exceeded 
1.5 standard deviations below age- and education-adjusted means was required for a diagnosis of 
MCI (Lopez et al., 2014; Snitz et al., 2013). A diagnosis of dementia required impaired 
performance on measures in two or more cognitive domains, with deficits significant enough to 
interfere with an ability to independently complete activities of daily living (Lopez et al., 2014). 
Consensus between a neurologist, a psychiatrist, and a neuropsychologist was required for a 
cognitive diagnosis (Snitz et al., 2013). Statistical models of cognitive outcomes will either include 
continuous measures of memory performance or binary/categorical variables reflecting cognitive 
status, based on the diagnoses given at baseline or follow-up (CN vs. MCI). 
 55 
The present study included two measures of memory performance: the California Verbal 
Learning Test (CVLT) and the Rey-Osterreith Complex Figure Test (Rey-O). Despite the 
availability of a full neuropsychological battery, we chose to focus on memory tasks in the present 
study 1) because delayed memory deficits are one of the earliest cognitive indicators of AD onset 
and 2) to prevent type 1 error inflation by reducing the number of analyses conducted. On the 
CVLT, participants were read aloud a 16-item list of words and asked to repeat the words from the 
list, with the total number of words recalled over 5 consecutive trials used as an estimate of list 
learning/immediate recall. After being read a distractor list, participants were asked to freely recall 
the original word list. After a 20-30 min delay, the participants were asked again to freely recall 
as many items from the 16-word list as possible. The total number of correct items (range 0 – 16) 
recalled was used as a continuous measure of delayed verbal memory. The cued recall trials were 
not included in the present analysis. Participants also completed the Rey-O, a measure of 
immediate and delayed visual memory. On this task, participants were asked to copy a complex 
figure comprising of a number of distinct elements. Participants were then asked to draw the figure 
from memory immediately after the copy trial, and once again 20-30 minutes later. A 36-point 
summary score, based on the accuracy of the 18 units/component contained within the figure was 
used to quantify immediate and delayed visuospatial memory performance. Each measure was 
converted to z-scores using standard deviations.   
2.4.2  Inflammatory blood assays 
Participants were asked to fast and to avoid exercise and alcohol for 12 hours prior to blood draw.  
Blood samples were collected at the GEMS closeout visit between October 2007 and March 2008 
and stored at -70oC until analyzed (Hughes, Lopez, et al., 2014).  Soluble CD14, CRP, ad IL-6 
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were measured using an enzyme-linked immunosorbant assay (ELISA) kit according to the 
manufacturers instructions (R&D Systems). The soluble receptors for TNF-α (TNF-αRI and TNF-
αRII) were measured using a Multiplex Panel (Millipore). Since TNF-α is cleared fairly quickly 
from circulation, soluble receptor levels reflect more stable measures of TNF-α activity.  
These inflammatory biomarkers will be used to predict cognitive status and Aβ pathology 
approximately 10 months after measurement and again 3 years following blood draw. Numerous 
longitudinal studies have measured the reliability of inflammatory markers over the course of 
months and years, and have found the biomarkers included in the present study to be moderately-
to-highly stable over time. Table 1 summarizes existing studies that have assessed the reliability 
of these particular biomarkers and includes information on cohort size, baseline age, follow-up 
time and estimate of stability over time, measured using either spearman’s correlation coefficient 
(r) or intraclass correlation coefficients (ICC) for each study.   
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Table 1. Reliability of peripheral biomarkers included in the present study. 
Biomarker Study Sample Size Age at Baseline Follow-up ICC/Corr. 
CD 14 
Epstein, 2013 200 21 - 55 (median 35) 2 years ICC = 0.57 
McKay, 2017 223 18.7-74.5 (median 45.6) 1.9 years ICC = 0.52 
Catelier, 2008 112 71.7 4-8 wks apart r = 0.60 
sTNF-RI 
Clendenen, 2010 18 42-62 2 years ICC = 0.31 
Hardikar, 2014 360 53 - 69 (61) 1.8 years ICC = 0.89 
Navarro, 2012 62 20-40 4-6 months ICC = 0.92 
Gu, 2010 65 35-65 (mean 50.8) 2 years ICC = 0.68 
sTNF-RII 
Clendenen, 2010 18 42-62 2 years ICC = 0.68 
Epstein, 2013 200 21 - 55 (median 35) 2 years ICC = 0.73 
Hardikar, 2014 360 53 - 69 (median 61) 1.8 years ICC = 0.85 
Navarro, 2012 62 20-40 4-6 months ICC = 0.90 
Gu, 2010 65 35-65 2 years ICC = 0.80 
McKay, 2017 223 18.7-74.5 (median 45.6) 1.9 years ICC = 0.71 
IL-6 
Alley, 2007 657 65-94 (mean 73.3) 3 years no avg. change 
Clendenen, 2010 18 42-62 2 years ICC = 0.81 
Epstein, 2013 200 21 - 55 (median 35) ICC = 0.55 
Gu, 2010 65 35-65 (mean 50.8) 2 years ICC = 0.92 
McKay, 2017 223 18.7-74.5 (median 45.6) 1.9 years ICC = 0.60 
Metti, 2015 135 70-79 10 years r = 0.47 
Nash, 2013 1,443 53-80+ 10 years % change = 14.8 
Citations for studies listed above: (Alley, Crimmins, Bandeen‐Roche, Guralnik, & Ferrucci, 2007; Catellier, Aleksic, 
Folsom, & Boerwinkle, 2008; Clendenen et al., 2010; Epstein et al., 2013; Gu et al., 2009; Hardikar et al., 2014; 
Jackson et al., 2015; McKay et al., 2017; Metti et al., 2015; Nash et al., 2013; Navarro et al., 2012; Out, Hall, Granger, 
Page, & Woods, 2012). 
2.4.3  Measures of covariates of interest in the current study 
2.4.3.1 APOE genotyping 
APOE genotyping of 3 major allelic forms of APOE (ε2, ε3, ε4) was performed on isolated DNA 
from plasma samples collected at the GEMS closeout visit (Hughes, Lopez, et al., 2014; Mathis et 
al., 2013) Frozen plasma samples were thawed and analyzed using an immunoturbidimetric 
procedure developed by Kamiya Biomedical Company (Hughes, Lopez, et al., 2014). A binary 
variable was created in which non-carriers were assigned a value of 0 and heterozygous and 
homozygous APOE ε4 carriers received a value of 1.   
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2.4.3.2 Lipid assays 
Stored plasma samples from the 2008 GEMS closeout visit were thawed and used to estimate 
triglyceride, total cholesterol, and high-density lipoprotein (HDL) cholesterol concentrations 
(Hughes, Lopez, et al., 2014). Conventional enzymatic methods were used to estimate lipid 
concentrations (Hughes, Lopez, et al., 2014), and low-density lipoprotein cholesterol levels were 
measured by the Friedewald equation (Friedewald, Levy, & Fredrickson, 1972). All apolipoprotein 
and lipid analyses were completed at the Heinz Nutrition Laboratory in the Department of 
Epidemiology at the University of Pittsburgh. 
Assessment for a history of cardiovascular disease was conducted, and a binary measure 
indicating a history of cardiovascular disease was created, and included myocardial infarction, 
congestive heart failure, coronary revascularization procedures, angina pectoris and peripheral 
vascular disease. Variables were also calculated categorizing participants based on the presence of 
hypertension (0 = absent, 1 = present) and diabetes (0 = absent, 1 = present) at baseline.  
2.4.3.3 Self-reported depressive symptoms 
Participants completed the 10-question Center for Epidemiologic Studies Depression Scale (CES-
D), yielding a continuous estimate of self-reported depressive symptoms, with higher values 
reflecting greater symptom burden.  
2.5 DATA ANALYSIS 
Ordinary least squares linear regression models were employed to investigate the cross-sectional 
and longitudinal associations between baseline inflammatory biomarkers, memory performance, 
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and Aβ plaque deposition/progression. As cognitive status was represented by a binary (CN or 
MCI), logistic regression models were used to assess the relationship between baseline 
inflammatory biomarkers and cognitive status at baseline and follow-up. Normality was examined 
for all variables, of which serum CD14, IL-6, and duration of time (weeks) between blood draw 
and PET imaging showed significant positive skew.  These measures were normalized by 
logarithmic transformation prior to analysis. All models were adjusted for age, gender, and years 
of education. Outliers were addressed using the winsorizing approach. For each variable, values 
that exceeded 3 standard deviations above or below the mean were identified and manually 
modified, such that outliers were assigned values that corresponded to the 95th or 5th percentiles, 
respectively. This is a conventional approach to addressing outliers, which allows us to retain 
subjects within the outlier range and continue to reflect their values in the upper/lower tails of the 
distribution while also minimizing skew.  
A strength of this study is  the availability of multiple inflammatory biomarkers including 
pro-inflammatory cytokines (or their corresponding receptor concentrations) IL-6, TNF-αRI, 
TNF-αRII, and cell surface receptor CD14. Given that little is known about the particular 
inflammatory markers associated with Aβ pathology, separate but identical statistical models were 
run for each inflammatory biomarker. To reduce the number of models run, concentrations of 
TNF-αRI and TNF-αRII were summed and averaged to reflect an overall estimate of soluble TNF-
α receptor concentrations. Although a small number of rodent models suggest that these two TNF-
α receptors may have different mechanisms of action in the CNS (Ramesh et al., 2013), the existing 
data is limited and this difference may not be reflected in peripheral receptor concentrations. Thus, 
each inflammatory variable served as continuous predictors in independent statistical models. 
Table 2 summarizes 1) the mechanisms of action of each of these inflammatory biomarkers under 
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conditions of immune challenge, 2) the evidence from animal and human studies that implicate 
these biomarkers in Aβ pathogenesis or AD onset, 3) the hypothesized relationship between each 
biomarker and the outcome variables of interest in the proposed study, and 4) the rationale used to 
support each hypothesis.  
Another strength of this study is the availability of both cognitively healthy participants 
and those with MCI, and the ability to discriminate between these subgroups. Widespread amyloid 
deposition and neurodegenerative changes take place prior to the onset of clinically detectable 
cognitive deficits, and therefore the preclinical phase, as defined by the NIA-AA, includes those 
exhibiting AD-related pathology but that do not meet diagnostic criteria for MCI.  In order to 
evaluate these relationships at the earliest possible point, it is critical to focus on populations that 
have not yet progressed to MCI. Therefore, all of the models described below were conducted in 
the combined sample (MCI + CN), and repeated after excluding subjects with MCI. In other words, 
all cross-sectional and longitudinal analyses conducted in the full samples were replicated in the 
subsample of CN participants, which allowed us to determine whether hypothesized relationships 
were observed in, or were specific to, asymptomatic populations.  In using this approach, we aimed 
to gain a better understanding of the temporal relationship between inflammatory biomarkers and 
amyloid burden. 
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Table 2. Inflammatory biomarkers, existing research, and specific hypotheses in the proposed study. 
 
 
Properties and 
functions Extant Research Hypothesis Rationale 
CD14 
Cell-surface 
receptor expressed 
by microglia; LPS 
receptor, monocyte 
activator 
Animals: CD14 facilitates binding of 
microglia to Aβ oligomers and 
fibrils, resulting in microglial 
activation (Heneka, 2015) and 
downstream inflammatory processes; 
knockdown of cell-surface receptors 
reduces cytokine production and Aβ 
aggregation 
In the PNS, binding of CD14 to LPS 
triggers synthesis and production of 
IL1β, TNF, IL-6 (Zamani et al., 2013) 
Elevated levels of CD14 
will be positively 
associated with MCI 
status at baseline, 
conversion to 
MCI/dementia at 
follow-up, and greater 
Aβ deposition at 
baseline and follow-up 
Facilitates activation of 
monocytes in PNS, may 
broadly reflect greater 
inflammatory burden with Aβ 
pathology; given the initial role 
of CNS CD14 in promoting the 
binding of Aβ to microglia, 
may also be up-regulated in 
periphery 
TNF-α 
(RI & II) 
Pro-inflammatory 
cytokine released by 
activated microglia, 
macrophages, 
neurons; mediates 
release of 
neurotoxic 
substances (ROS, 
iNOS), apoptosis, 
activates astrocytes 
Animals: TNF-α overexpressed in 
AD transgenic mice (Wang, 2015); Aβ 
species promote production of TNF-α 
(Heneka, 2015); blocking TNF-α signaling 
reduces Aβ plaques (Wang, 2015); TNF-α 
contributes to APP processing (Wang 
2015), stimulates release of reactive 
nitrogen species (Rubio-Perez, 2012), 
impairs BBB integrity (Calsolaro, 2016), and 
penetrate BBB from periphery  
Humans: elevated levels of TNF-α 
surrounding amyloid plaques in brain 
tissue of AD patients (Calsolaro, 2014); 
elevated peripheral levels in 
individuals with AD (Swardfager 2010), 
greater serum TNF-α levels 
assozciated with more rapid rate of 
decline over 6 months (Walters, 2015) 
 
Peripheral concentrations elevated in 
metabolic syndrome (Srikanthan, 2014) 
 
Elevated levels of TNF-
α (RI and RII) be 
positively associated 
with MCI status at 
baseline, conversion to 
MCI/dementia at 
follow-up, and greater 
Aβ deposition at 
baseline and follow-up 
 
Will positively mediate 
relationship between 
CVD risk factors and 
Aβ deposition 
In rodents, TNF-α perpetuates 
Aβ, impairs BBB; in humans 
elevated in post-mortem brain 
tissue of AD, increased 
peripheral concentrations 
assoc. with cognitive 
impairment 
 
Mediating effect due to TNF-α 
associations with obesity, 
insulin resistance, metabolic 
syndrome 
IL-6 
Pro-inflammatory 
cytokine produced 
by microglia and 
astrocytes in CNS; 
macrophages, T 
cells, adipose tissue 
in PNS; induces 
acute-phase 
response; in PNS 
may inhibit TNF-α 
production; in CNS 
activates microglia, 
promotes 
astrogliosis, release 
of cytotoxic 
substances 
Animals: IL-6 activates 
microglia/macrophages; Aβ species 
promote production of IL-6 (Heneka, 
2015); IL-6 contributes to APP 
processing (Wang, 2015), stimulates 
release of reactive nitrogen species 
(Rubio-Perez, 2012), able to impair BBB 
integrity (Calsolaro, 2016) and penetrate 
BBB from the periphery 
Humans: elevated levels of IL-6 
surrounding amyloid plaques in brain 
tissue of AD patients (Calsolaro, 2014); 
elevated peripheral concentrations in 
individuals with AD(Swardfager et al.,); 
predicts risk of incident dementia 3-8 
years later (Engelhart, 2004) 
Peripheral concentrations elevated in 
metabolic syndrome (Srikanthan, 2014) 
IL-6 will be positively 
associated with MCI 
status at baseline, 
conversion to 
MCI/dementia at 
follow-up, and greater 
Aβ deposition at 
baseline and follow-up 
 
Will positively mediate 
relationship between 
CVD risk factors and 
Aβ deposition 
 
In animals, IL-6 contributes to 
APP processing, microglial 
priming, impairs BBB, can 
penetrate BBB from periphery; 
in humans elevated in post-
mortem brain tissue of AD, 
predicts future risk of incident 
dementia, suggesting possible 
role of IL-6 early in disease 
course 
 
Mediating effect due to 
associations with obesity, 
insulin resistance, metabolic 
syndrome 
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Aim 1 assessed the cross-sectional associations between baseline inflammatory markers, 
cognitive status, and memory performance (n = 173). Using logistic regression models, cognitive 
status was represented by a binary variable reflecting CN subjects and those with a baseline 
diagnosis of MCI, using CN participants as the reference group. A series of linear regression 
models assessed the relationship between each inflammatory marker and memory performance. 
To this end, each subjects’ performance on a visual memory task (Rey-O) and a verbal memory 
task (CVLT) was z-scored, summed, and averaged to yield a continuous composite measure of 
global or general memory performance. To distinguish associations with verbal versus visual 
memory performance, two additional z-scores were calculated, one which reflects average 
performance on immediate and delayed trials of the CVLT, and the second representing 
performance on the Rey-O. 
Aim 2 assessed the cross-sectional associations between baseline inflammatory markers 
and fibrillar Aβ plaque deposition (n = 173). This model also examined whether the relationship 
between inflammatory markers and Aβ plaque deposition varied as a function of preclinical disease 
stage. According to the NIA-AA guidelines, an Aβ+/ND- imaging profile represents the initial 
preclinical stage, while the combination of significant Aβ deposition and neurodegeneration 
reflects the second neuropathological phase of preclinical AD. Hippocampal atrophy was used as 
a proxy for neurodegeneration, and was included as a moderator in linear regression models. In 
other words, consistent with other cross-sectional studies (Bilgel et al., 2017, Mormino et al., 2014, 
Zhao et al., 2018), hippocampal atrophy served as an indicator of where subjects may fall on the 
preclinical continuum. Thus, along with covariates, each model included a continuous 
inflammatory marker, a binary variable (W-score) representing neurodegeneration status (ND+ vs. 
ND-), and their interaction product. Along with W-score, hippocampal volume, calculated as a 
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proportion of total ICV (e.g., sum of right and left hippocampi/ICV), was included in separate 
moderation models to provide a continuous estimate of hippocampal atrophy. Thus, regression 
models included age, gender, and education level as covariates, inflammatory biomarker and 
hippocampal atrophy as independent predictors, and their interaction product (inflammatory 
biomarker X hippocampal atrophy). A continuous measure of global amyloid burden was used as 
the primary dependent variable in main effect and moderation models.  
Given that, to our knowledge, only one existing study has examined associations between 
peripheral inflammatory biomarkers and regional PiB uptake in humans, we also assessed whether 
these relationships were global or spatially distinct. Therefore, for inflammatory variables that 
demonstrated significant main or interaction effects on global PiB-PET retention, subsequent 
secondary hierarchical regression analyses were run using template-based ROIs to assess the 
possible regional specificity of these associations. Given 1) that this is a preclinical/MCI sample 
and 2) the established hierarchical nature of early amyloid progression, we hypothesized that the 
relationship between peripheral biomarkers and PiB uptake would be specific to (or strongest in) 
regions particularly vulnerable to Aβ accumulation in the earliest phases of amyloidosis, which 
included 3 ROI’s: the anterior cingulate gyrus, frontal cortex, and precuneus. These were 
considered a priori ROIs, and thus the alpha threshold for significance was set at 0.05. Owing to 
the exploratory nature of this work, we also assessed whether these relationships were apparent in 
other cortical and subcortical regions. This included 8 additional template-derived ROIs (anterior 
ventral striatum, lateral temporal, mesial temporal cortex, occipital cortex, occipital pole, parietal 
cortex, sensory-motor cortex, and the thalamus). To prevent type 1 error inflation, a Bonferonni 
threshold was applied to models including the 8 ROI’s considered exploratory or post hoc, 
resulting in a corrected p-value of 0.004 (e.g., 0.05/8).  
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Finally, to examine the influence of potential confounding variables including comorbid 
cardiovascular and health factors, each model was re-run adjusting for demographic characteristics 
as well as history of heart disease, diabetes, and hypertension, all represented by binary variables 
reflecting the presence or absence of each health factor, and a continuous measure of self-reported 
depressive symptoms. Given the association between peripheral inflammatory biomarkers and 
white matter lesions, white matter hyperintensities (a continuous measure quantified as volume of 
white matter lesions/total brain volume) were controlled for in secondary analyses. Also entered 
was a variable reflecting time since blood draw, which was calculated as the number of weeks 
between blood sample collection (from which inflammatory biomarkers were quantified) and 
baseline PiB-PET neuroimaging. Given the variability of inflammatory biomarker expression over 
time, this allowed us to adjust for individual differences in the time that had elapsed between blood 
sample collection and image acquisition. Finally, there is a well-established and robust association 
between APOE ε4 carrier status and Aβ burden (Kantarci et al., 2012; Lim, Ellis, et al., 2013), and 
we explored whether the relationship between inflammatory factors and PiB retention existed 
independently of APOE ε4 genotype. Therefore, participants were dichotomized into non-carriers 
and carriers (combining heterozygous and homozygous carriers) and included in a third set of 
sensitivity models to explore whether observed associations remained after additional adjustment 
for APOE ε4 status.  
Aim 3 leveraged longitudinal data collected in a subsample of participants to investigate 
whether inflammatory biomarkers predicted conversion of cognitive status or change in memory 
performance over the two-year follow-up period (n = 90). A series of logistic regression models 
were used to assess whether each inflammatory biomarker predicted cognitive diagnosis at follow-
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up (e.g., MCI or CN at follow-up in a combined longitudinal sample), as well as conversion from 
CN to MCI among those that were cognitively healthy at baseline.  
Residualized change scores were calculated and used as dependent variables in linear 
regression models, to explore the relationship between inflammatory markers and longitudinal 
change in memory performance from baseline (T1) to follow-up (T2). Thus, for each outcome 
variable of interest, cognitive performance at T2 was regressed on T1 to generate a residual. The 
estimated residuals reflected the deviation between the predicted value (based on T1) and the actual 
value (T2), thus reflecting change from T1 to T2. This approach is preferable to a raw difference 
score as residualized change scores estimate change over time while also adjusting for the values 
of each outcome variable of interest at baseline. Estimating change over time after correcting for 
baseline levels of each variable provides a purer measure of change that is unaffected by individual 
differences in variables of interest at baseline. 
Aim 4 examined whether baseline serum concentrations of inflammatory mediators 
predicted progression of Aβ plaque deposition over the 2-year follow-up (n = 90). To this end, 
change in Aβ deposition between the two consecutive scans was estimated by regressing PiB 
retention at T2 on T1. This resulted in unstandardized residuals for global and regional PiB uptake, 
which were used as dependent variables in longitudinal models and reflect change in Aβ plaque 
deposition after adjusting for individual differences in Aβ pathology at baseline.  Baseline 
hippocampal atrophy was included as a moderator in statistical models, as well as the hippocampal 
volume X inflammatory biomarker interaction term, to assess whether the relationship between 
each biomarker and Aβ progression was greater in magnitude among subjects that also exhibited 
significant hippocampal atrophy. The regional specificity of these relationships was also 
investigated in longitudinal models. A hand-drawn region of interest approach was applied to the 
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PiB-PET data of subjects that completed both the baseline and follow-up scans, which yielded 
more distinct ROI’s than the template-based ROI approached used in the full baseline sample (e.g., 
anterior cingulate ROI, superior anterior cingulate ROI, and pregenual anterior cingulate ROI). 
Therefore, a two-tailed alpha of p = 0.05 was used to define statistical significance for those ROI’s 
considered a priori (e.g., precuneus and frontal ROIs), while a Bonferroni correction threshold 
was applied to any remaining ROI’s (0.05/7 = 0.007) assessed. To further reduce the number of 
models, only ROI’s that exhibited main or interaction effects in cross-sectional analyses were 
evaluated in longitudinal models. Among models that achieved significance when controlling for 
participant demographics, follow-up hierarchical analyses were conducted that further adjusted for 
Aβ-relevant factors, including cardiovascular risk factors, mood, white matter lesions, and APOE 
genotype. 
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3.0 RESULTS 
3.1 CROSS-SECTIONAL RESULTS 
3.1.1  Subject characteristics 
Of the 194 participants included in the GEM Neuroimaging Substudy, 190 had complete blood 
data collected in 2008, from which serum concentrations of inflammatory biomarkers were 
quantified. Four subjects were missing inflammatory data and were excluded from analyses. 
Another 5 participants had C-reactive protein values that exceeded 10 mg/L, suggesting that they 
may have been ill at the time of blood draw, and were therefore excluded from analyses. An 
additional 8 subjects were missing intracranial volume data and were excluded, as this was 
required to calculate the proportion of hippocampal volume to total brain volume. Finally, in order 
to focus exclusively on subjects without dementia, the 4 participants that met criteria for dementia 
during the baseline 2009 neuropsychological assessment were excluded from all analyses. The 
final baseline sample consisted of 173 participants.  
The average age of the 173 participants included in the present study was 85.45 (SD = 
2.84), with ages ranging from 82-95. Women comprised 40.5% of the sample (N = 70), all but 6 
subjects were Caucasian (96.5%), and participants had an average of 14.64 years of education (SD 
= 2.65). Thirty-four participants were diagnosed with MCI at baseline (19.7%), including 24 with 
amnestic MCI and 10 with non-amnestic MCI. Ninety-four participants (54.3%) were classified as 
amyloid positive and 79 (45.7%) were considered amyloid negative using a standard iterative 
outlier method (defined as PiB+ if global Aβ > 1.57) (Nadkarni et al., 2017). Of the full sample, 
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33 subjects (19.1%) were carriers of the APOE ε4 genotype. Associations between predictors and 
covariates of interest were assessed using two-tailed t-tests and bivariate correlations. IL-6 was 
moderately correlated with CD14 (r = 0.30; p < 0.001) and TNF-α (r = 0.27; p < .001). The 
relationship between CD14 and TNF-α was moderate but slightly larger in magnitude (r = 0.37; p 
< 0.001) (Table 3). Baseline characteristics, including, age, education level, gender, APOE carrier 
status, history of heart disease, and presence of diabetes or hypertension, did not differ between 
the CN subjects (N = 139) and those with MCI (N = 34). As would be expected, cognitively healthy 
participants performed significantly better on the MMSE (t = -4.21; p < 0.001) and had larger 
hippocampal volumes on average (t = -4.08; p < 0.001) relative to those with MCI. Table 4 includes 
the descriptive statistics for the combined baseline sample and the CN and MCI subsamples. Even 
prior to adjusting for demographic factors, there was no significant relationship between 
hippocampal volume and any of the 3 inflammatory biomarkers in bivariate correlation models. 
This is the case for the full sample, and the CN subsample.  
 
Table 3. Bivariate correlations between inflammatory biomarkers in the full baseline sample (N = 173). 
 IL-6 CD14 TNF-α  
(avg) 
TNF-α R1 TNF-α RII 
IL-6 1     
CD14 .299* 1    
TNF-α (avg) .271* .370* 1   
TNF-α R1 .231* .255* .782* 1  
TNF-α RII .264* .374* .990** .688** 1 
                *Correlations are significant at 0.01 (2-tailed). 
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Table 4. Demographic, inflammatory, health, and cognitive characteristics for combined baseline sample and the CN 
and MCI subsamples. 
 Combined 
Sample CN MCI 
 N = 173 N = 139 N = 34 
 % (N) or M (SD) % (N) or M (SD) % (N) or M (SD) 
Age 85.45 (2.84) 85.36 (2.84) 85.79 (2.83) 
Gender (% F) 40.5 (70) 43.2 (60) 29.4 (10) 
Education 14.64 (2.65) 14.79 (2.65) 14 (2.58) 
ApoE, % (N) 19.1 (33) 19.4 (27) 17.6 (6) 
Hx Heart Disease, % (N) 17.3 (30) 15.1 (21) 26.5 (9) 
Diabetes, % (N) 5.8 (10) 5.2 (7) 8.8 (3) 
Hypertension, % (N) 34.1 (59) 32.4 (45) 41.2 (14) 
MCI, % (N) 19.7 (34) - - 
MMSE 27.62 (2.10) 28.04 (1.67) 25.94 (2.74) 
CD14 1359.28 (261.04) 1367.61 (256.47) 1325.23 (280.37) 
TNF-α 3842.16 (1077.41) 3791.89 (1013.95) 3980.75 (1147.61) 
IL-6 2.63 (1.62) 2.56 (1.54) 2.9 (1.93) 
Weeks from blood 
draw to PET 
87.26 (38.34) 
range 50.4-331.1 
88.84 (42.12) 
range 50.6 - 331 
81.68 (13.95) 
range 58.4 - 115.6 
PiB+ (%) 54.3 (94) 51.8 (72) 64.7 (22) 
CVLT Immediate 43.10 (12.09) 45.7 (11.14) 32.47 (9.91) 
CVLT Delay 8.25 (3.73) 9.19 (3.21) 4.38 (3.17) 
Rey Immediate 16.18 (3.92) 17.01 (3.50) 12.77 (3.73) 
 
3.1.2  Inflammatory biomarkers, cognitive diagnosis, and memory performance 
3.1.2.1 Combined sample 
Logistic regression models were employed to assess the association between inflammatory 
biomarkers and cognitive diagnosis at baseline. After adjusting for age, gender, and years of 
education, using CN subjects as the reference group, there were no significant associations 
between IL-6 (odds ratio (OR) = 1.17; p = 0.44), TNF-α (OR = 1.05; p = 0.81), or soluble CD14 
(OR = 0.84; p = 0.40) and diagnostic status at baseline.  These non-significant findings were 
unchanged after excluding the 10 subjects diagnosed with non-amnestic MCI.  
Specific associations within the memory domain were also evaluated, using three 
continuous composite scores reflecting average performance on two memory tasks: the Rey-O and 
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the CVLT. This included an estimate of inter-task or global memory performance (average of 
immediate and delayed trials on both tasks), verbal memory performance (average of immediate 
and delayed CVLT trials), and visual memory performance (average of immediate and delayed 
Rey-O trials). Multivariable linear regression models revealed that elevated levels of IL-6 
predicted poorer global memory performance (p = 0.044; β = -0.148; R2 change = 0.021). Probing 
this relationship using task-specific composite scores revealed no significant association between 
IL-6 and Rey-O performance, and a trending relationship with performance on immediate and 
delayed trials of the CVLT (p = 0.055; β = -0.133; R2 change = 0.017). Regression models 
including TNF-α and CD14 as independent predictors demonstrated no significant associations 
between each biomarker and cognitive performance in the combined sample. Hippocampal volume 
was positively associated with better performance on all z-score estimates.  
3.1.2.2 Cognitively healthy subsample 
These analyses were repeated in the subsample of subjects deemed CN at the time of imaging to 
assess associations between inflammatory biomarkers and memory performance exclusively 
among subjects without clinically significant cognitive impairment (e.g., those in the 
asymptomatic, preclinical phase). Among the 139 CN participants, the presence of elevated IL-6 
was associated with worse global memory performance in adjusted models (β = -0.187; p = 0.024). 
In contrast to the findings in the combined sample, the inverse association between IL-6 
concentrations and CVLT performance reached significance (β = -0.171; p = 0.027). The 
association between IL-6 and Rey-O performance remained non-significant (β = -0.121; p = 
0.161).  
Contrary to the null results observed in the combined sample, restricting the analysis to the 
139 CN subjects revealed that lower peripheral concentrations of TNF-α were associated with 
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better verbal memory performance on the CVLT (β = -0.20; p = 0.015). There were no significant 
associations between TNF-α and the remaining memory composites (p > 0.05). CD14 was not 
associated with the global memory composite, nor did it predict task-specific performance. 
Parameter estimates from regression models predicting cognitive performance are included in 
Tables 5 and 6. 
Table 5. Associations between IL-6 and cognitive performance on two memory tasks, after adjusting for age, 
gender, and years of education. 
Global Memory 
Performance 
Verbal Memory 
Performance (CVLT) 
Visual Memory 
Performance (Rey-O) 
Combined Sample (MCI and Cognitive Healthy) N = 173 
IL-6 
P = 0.044; 
β = -0.148 
R2 change = 0.021 
P = 0.055; 
β = -0.133 
R2 change = 0.017 
P = 0.142; 
β = -0.113 
R2 change = 0.012 
Cognitively Healthy Subjects (MCI subjects excluded) N = 139 
IL-6 
P = 0.024; 
β = -0.187 
R2 change = 0.034 
P = 0.027; 
Β = -0.171 
R2 change = 0.028 
P = 0.161; 
β = -0.121 
R2 change = 0.012 
  Bolded values are significant at p < 0.05. 
Table 6. Associations between TNF-α and cognitive performance on two memory tasks, after adjusting for age, 
gender, and years of education. There were no significant TNF x hippocampal volume interactions. 
Global Memory 
Performance 
Verbal Memory 
Performance (CVLT) 
Visual Memory 
Performance (Rey-O) 
Combined Sample (MCI and Cognitive Healthy) N = 173 
TNF-α 
P = 0.148; 
β = -.114 
R2 change = 0.011 
P = 0.197 
β = -.096 
R2 change = 0.008 
P = 0.256; 
β = -0.093 
R2 change = 0.007 
Cognitively Healthy Subjects (MCI subjects excluded) N = 139 
TNF-α 
P = 0.076; 
β = -0.157 
R2 change = 0.021 
P = 0.015; 
Β = -0.20 
R2 change = 0.034 
P = 0.628; 
β = -0.045 
R2 change = 0.002 
                   Bolded values are significant at p < 0.05. 
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3.1.3  Main effects of inflammatory biomarkers on global and regional PiB retention 
3.1.3.1 Combined sample 
To explore the cross-sectional relationships between inflammatory mediators, neurodegeneration, 
and Aβ accumulation, hierarchical regression models were conducted including inflammatory 
biomarkers and hippocampal volume as independent predictors, as well as their interaction 
product. Identical regression models were conducted separately for each of the 3 inflammatory 
biomarkers. The main effects are summarized here, and the interaction effects are reported in the 
subsequent section. After adjusting for age, gender, and education level, hierarchical linear 
regression models revealed a direct association between soluble CD14 and global PiB uptake, such 
that higher serum concentrations of CD14 predicted greater global Aβ deposition (β = 0.161; p = 
0.039). Holding hippocampal volume constant, there were no main effects of TNF-α (p = 0.24; β 
= 0.98) or IL-6 (p = 0.226; β = -0.094) on global PiB uptake. Hippocampal volume was not 
independently associated with global PiB SUVR retention.  
The observed association between CD14 and global Aβ deposition warranted secondary 
analyses using template-derived ROI’s to evaluate the possible regional specificity of these 
relationships. Therefore, multiple linear regression models were fit to explore associations between 
CD14 and continuous measures of regional PiB SUVR while controlling for age, gender, and 
education level. The three regions that were considered a priori ROI’s, the anterior cingulate gyrus, 
frontal cortex, and precuneus, were assigned a standard significance threshold of p < 0.05.  To 
adjust for multiple comparisons, a Bonferroni correction was applied to the remaining 8 ROI’s, 
yielding an adjusted alpha set at p < 0.004. Secondary analyses showed that higher serum CD14 
was positively associated with regional amyloid burden in the anterior cingulate gyrus (β = 0.170; 
p = 0.029), frontal cortex (β = 0.173; p = 0.026), and mesial temporal cortex (β = 0.24; p = 0.002) 
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(Figure 3). While positive associations between serum CD14 and Aβ deposition in the thalamus 
(β = 0.18; p = 0.020), occipital cortex (β = 0.18; p = 0.021), and occipital pole (β = 0.171; p = 
0.030) were also observed, they did not survive correction for multiple comparisons.  
 
 
           A. Global PiB Retention                                             B. Anterior Cingulate Gyrus 
 
      
 
 
 
 
 
 
 
 
 
 
 
 
          C.  Frontal Cortex                                                          D. Mesial Temporal Lobe  
 
        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Cross-sectional associations between CD14 and global and regional PiB retention in the 
CN subsample (N = 139). 
 
A series of exploratory models also evaluated whether the relationship between 
inflammatory biomarkers and PiB uptake existed independently of other factors known to predict 
amyloid burden, including vascular health, mood, and APOE ε4 genotype. Therefore, hierarchical 
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models controlled for demographic factors, history of heart disease, hypertension, diabetes, white 
matter hyperintensities, APOE genotype, depressive symptoms, and duration (weeks) between 
blood draw and PET imaging. Conservatively adjusted models included 145 observations, as some 
participants were missing APOE and/or white matter imaging data. The associations between 
soluble CD14 and global and regional PiB retention were no longer significant after controlling 
for the aforementioned covariates (all p > 0.05), even prior to adjusting for APOE ε4.  
3.1.3.2 Cognitively healthy subsample 
After excluding the 34 individuals with MCI, we found a trending, but non-significant association 
between CD14 and global PiB retention such that higher levels of CD14 were associated with 
greater global PiB retention (β = 0.159 p = 0.068). Regarding regional amyloid burden, the 
relationship between CD14 and PiB uptake in the anterior cingulate (β = 0.175; p = 0.044) persisted 
in the CN subsample, while this relationship no longer reached statistical significant in the frontal 
cortex (β = 0.164; p = 0.059). Elevated levels of CD14 were associated with greater amyloid 
burden in the mesial temporal lobe, although this relationship did not survive correction for 
multiple comparisons (β = 0.230; p = 0.007). None of the remaining ROIs were related to serum 
CD14, even prior to applying the Bonferroni correction. Consistent with the findings in the full 
sample, the total amount of Aβ deposition in the brain was not associated with either TNF-α or IL-
6 in main effects models. 
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3.1.4  Inflammatory biomarkers, hippocampal volume, and global/regional PiB 
3.1.4.1 Combined sample 
To examine whether the association between inflammatory biomarkers and amyloid burden varied 
as a function of neurodegeneration, two estimates of hippocampal atrophy were included as 
moderators in hierarchical linear models. The first series of models incorporated W-score as a 
binary indicator of hippocampal neurodegeneration. Seven subjects were missing W-scores, 
therefore moderation models including this variable contained 166 observations. There were no 
significant interaction effects on global PiB-PET deposition for CD14, TNF-α, or IL-6 when 
binary W-score was used as a moderator (all p > 0.05). Given the lack of significant associations 
with global Aβ deposition, secondary moderation models evaluating regional PiB uptake were not 
conducted.  
A second series of linear regression models were conducted using a continuous estimate of 
normalized hippocampal volume as a predictor and moderator in interaction terms. The 
relationship between TNF-α and global PiB retention was moderated by hippocampal volume, 
such that higher levels of TNF-α predicted elevated global amyloid burden among those with 
greater hippocampal atrophy (β = -.172; p = 0.024; R2 change = 0.029). A significant interaction 
effect was also observed between IL-6 and hippocampal volume on global amyloid deposition (p 
= 0.012; β = -.192; R2 change = 0.036). Hippocampal volume did not moderate the association 
between serum CD14 and global amyloid deposition (β = -.104; p = 0.175).  
Significant interaction effects on global PiB retention merited secondary analyses 
exploring the conditional associations between inflammatory biomarkers and regional amyloid 
deposition as a function of hippocampal volume. Using template-derived ROI’s, these analyses 
revealed a synergistic relationship between TNF-α and hippocampal volume on PiB retention in 
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the anterior cingulate (p = 0.027; β = -.169; R2 change = 0.028), frontal cortex (p = 0.033; β = -
.163; R2 change = 0.026), and precuneus (p = 0.027; β = -.168; R2 change = .028) ROIs. Interaction 
effects in the occipital cortex (p = 0.024; β = -.170; R2 change = 0.028) and occipital pole ROI’s 
(p = 0.012; β = -.193; R2 change = 0.036) did not meet multiple comparison thresholds. Similar 
interaction effects were observed in models using IL-6 as a predictor, including associations with 
regional Aβ deposition in the anterior cingulate gyrus (p = 0.015; β = -.184; R2 change = 0.033), 
frontal cortex (p = 0.020; β = -.177; R2 change = 0.031), and precuneus (p = 0.009; β = -.196; R2 
change = 0.038). Associations were also observed in the occipital cortex (p = 0.019; β = -.178; R2 
change = 0.031) and the sensory-motor cortex (p = 0.013; β = -.188; R2 change = 0.035), but were 
no longer significant after multiple comparison correction. Across all models, interaction terms 
explained an additional 2.5-5% of the variation in PiB retention, above and beyond covariates and 
independent predictors. 
To probe significant inflammatory biomarker X hippocampal volume interactions, we 
chose several conditional values of hippocampal volume at which to evaluate the significance of 
the simple slopes for the regression of global PiB retention on IL-6 and TNF-α. To this end, the 
linear regression analyses were recomputed using hippocampal variables re-centered to reflect the 
degree of hippocampal atrophy. Thus, using separate statistical models, we assessed main effects 
of both IL-6 and TNF-α on Aβ deposition at the mean, 1 standard deviation above, and 1 standard 
deviation below the mean hippocampal volume.  This analysis allowed us to examine where along 
the hippocampal volume continuum the slopes start to differ between those with varying levels of 
inflammatory biomarker expression. There was not a significant main effect of IL-6 or TNF-α in 
the regression models using mean-centered hippocampal volume (p > 0.05). In contrast, simple 
slope analyses revealed that, for both biomarkers, elevated concentrations of inflammatory 
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mediators predicted greater PiB deposition when hippocampal volume was mean-centered at 1 
standard deviation below the mean (TNF-α: p = 0.016; β = 1.22; IL-6: p = 0.008; β = 1.53). There 
was also a main effect of both biomarkers when hippocampal volume was centered at 1 SD above 
the mean, such that global PiB retention remained stable across varying levels of cytokine 
expression among those exhibiting minimal hippocampal atrophy (TNF-α: p = 0.017; β = 1.53; 
IL-6: p = 0.008; β = 1.94). Thus, the relationship between inflammatory mediators and Aβ load 
varied as a function of hippocampal volume, such that elevated levels of both inflammatory 
markers (IL-6 and TNF-α) predicted greater Aβ deposition specifically among those that also 
displayed greater hippocampal atrophy (results from simple slope analyses depicted in Figures 4 
& 5). 
Notably, for both IL-6 and TNF-α, moderation models remained significant following 
additional adjustment for history of heart disease, hypertension, diabetes, white matter 
hyperintensities, depressive symptoms, and time from blood biomarker collection to PET imaging 
(N=156 for conservatively adjusted models due to reduced number of participants that completed 
white matter imaging). Interaction terms also withstood additional adjustment for APOE ε4 status 
in a third set of sensitivity models (N = 146). In hierarchical models, APOE ε4 genotype was the 
strongest predictor of global PiB retention, explaining 14.1% of the variance, followed by 
depressive symptoms (5.1% variance explained), and then interaction terms (IL-6: 3.6%; TNF-α: 
2.9%). Thus, the amount of variance attributable to the interaction terms was greater than the 
combined variance explained by demographic characteristics (1%) and history/presence of 
cardiovascular risk factors (1.9% combined (hx heart disease, diabetes hypertension)). 
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Figure 4. Results from simple slope analysis in the combined sample (N = 173), illustrating the linear associations 
between IL-6 and global PiB retention across several condittional values of hippocampal volume. 
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Figure 5. Results from simple slope analysis in the combined sample, illustrating the linear associations between 
TNF-α and global PiB retention across several conditional values of hippocampal volume. 
Finally, we conducted a post hoc analysis to evaluate whether interaction effects would 
persist after restricting the analyses to the 94 subjects classified as PiB+ based on conventional 
dichotomous thresholds. Similar to the full sample, there was no main effect of hippocampal 
volume (β = -0.146; p = 0.198), IL-6 (β = 0.142; p = 0.21) or TNF-α on global PiB uptake (β = 
-.03; p = 0.783). The interaction between IL-6 and hippocampal volume remained significant (β 
= -.224; p = 0.033). Despite the reduced sample size, the amount of variance explained by 
the interaction term was larger than that observed in the full sample (R2 = .048). The TNF-α 
interaction term failed to reach statistical significance (β = -.097; p = 0.361; R2 change = .009). 
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3.1.4.2 Cognitively healthy subsample 
The interaction between TNF-α and hippocampal volume on global PiB retention remained 
significant when restricting the analysis to cognitively healthy participants (p = 0.027; β = -0.191; 
R2 change = .036). Interaction terms were also significant with respect to regional PiB uptake in 
the anterior cingulate cortex (p = 0.040; β = -.178; R2 change = .031), frontal cortex (p = 0.039; β 
= -.178; R2 change = .031), and precuneus (p = 0.010; β = -.220; R2 change = .048). The interaction 
terms were not significant for the remaining regional PiB-PET ROIs. Parameter estimates and 
statistical significance remained stable in all models after additional adjustment for history of heart 
disease, hypertension, diabetes, white matter hyperintensities, depressive symptoms, and time 
from blood draw to PET imaging acquisition (N = 124 in conservatively adjusted models). 
However, further adjustment for APOE ε4 status in exploratory, sensitivity models (N = 117) 
attenuated regional interaction effects in the anterior cingulate and frontal cortex, although results 
were trending (anterior cingulate gyrus: β = -1.312 p = 0.076; frontal cortex: β = -1.418; p = 0.052). 
The interactions between IL-6 and hippocampal volume on PiB retention globally (p = 
0.047; β = -.173; R2 change = 0.027) and in the precuneus ROI (p = 0.024; β = -0.195; R2 change 
= 0.037) remained in the CN subsample, but was trending and no longer significant in the anterior 
cingulate (p = 0.066; β = -.160; R2 change = 0.025) and frontal cortex ROI’s (p = 0.068; β = -.159; 
R2 change = 0.025). The interaction terms withstood correction for demographic factors as well as 
history of heart disease, hypertension, diabetes, white matter hyperintensities, depressive 
symptoms and APOE ε4 carrier status (N = 117). Furthermore, the interaction term reached 
significance in the frontal cortex after adjusting for the aforementioned nuisance variables (p = 
0.038; β = -.188; R2 change = 0.032). Parameter estimates for main effect and interaction terms 
for models including IL-6 and TNF-α are included in Tables 7 and 8. For visualization purposes, 
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results from the simple slope analyses predicting global PiB retention are depicted in Figure 6 and 
Figure 7. 
Including interaction terms in statistical models explained an additional 2.5-5% of the 
variance in global and regional PiB deposition in the CN subsample. Similar to the combined 
sample, APOE genotype explained the largest amount of variance in global PiB uptake (11.8%), 
followed by depressive symptoms (4.9%), with the interaction term accounting for the third largest 
amount of variance in conservatively adjusted models, explaining between 2.9% (IL-6) - 3.6% 
(TNF-α) of the variance above and beyond all other predictors (total variance in global PiB 
retention explained = 20.1%). 
 
Table 7. Main effects of IL-6 and hippocampal volume on global and regional PiB uptake, as well as their 
interaction terms (IL-6 X hippocampal volume), in the combined baseline sample (top section) and in the CN subset 
(bottom section). 
N = 173 Global PiB Anterior Cingulate 
Gyrus Frontal Cortex Precuneus 
Combined Sample (MCI & CN) N = 173 
            IL-6 P = 0.226; 
β = 0.094 
P = 0.182; 
β = 0.103 
P = 0.178; 
β = 0.105 
P = 0.214; 
β = 0.096 
Hippocampal 
Volume/ICV 
P = 0.135; 
β = -0.121 
P = 0.191; 
β = -0.105 
P = 0.152; 
β = -0.116 
P = 0.043; 
β = -0.162 
IL-6 X 
Hippocampal 
Volume 
P = 0.012; 
β = -0.192 
R2 change = 0.036 
P = 0.015; 
β = -0.184 
R2 change = 0.033 
P = 0.020; 
β = -0.177 
R2 change = 0.031 
P = 0.009; 
β = -0.196 
R2 change = 0.038 
Cognitively Healthy Subjects (MCI subjects excluded) N = 139 
N = 139 Global PiB Anterior Cingulate 
Gyrus Frontal Cortex Precuneus 
IL-6 P = 0.667; 
β = 0.038 
P = 0.603; 
β = 0.046 
P = 0.540; 
β = 0.054 
P = 0.646; 
β = 0.040 
Hippocampal 
Volume/ICV 
P = 0.210; 
β = -0.115 
P = 0.305; 
β = -0.094 
P = 0.194; 
β = -0.118 
P = 0.086; 
β = -0.156 
IL-6 X 
Hippocampal 
Volume 
P = 0.047; 
β = -0.173 
R2 change = 0.029 
P = 0.066; 
β = -0.160 
R2 change = 0.025 
P = 0.068; 
β = -0.159 
R2 change = 0.025 
P = 0.024; 
β = -0.195 
R2 change = 0.037 
Bolded values significant at p < 0.05. All models adjusting for age, gender, and years of education.  
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Figure 6. Results from simple slope analysis in the CN subsample (N = 139), illustrating the linear associations 
between IL-6 and global PiB retention across several conditional values of hippocampal volume. 
 
Table 8. Main effects of TNF-α and hippocampal volume on global and regional PiB uptake, as well as their 
interaction terms (TNF X hippocampal volume), in the combined sample (top section) and in the CN subset (bottom 
section). 
N = 173 Global PiB Anterior Cingulate 
Gyrus Frontal Cortex Precuneus 
Combined Sample (MCI & Cognitively Healthy) N = 173 
TNF-α P = 0.235; 
β = 0.098 
P = 0.337; 
β = 0.079 
P = 0.318; 
β = 0.083 
P = 0.225; 
β = 0.099 
Hippocampal 
Volume/ICV 
P = 0.107; 
β = -0.130 
P = 0.151; 
β = -0.115 
P = 0.118; 
β = -0.126 
P = 0.032; 
β = -0.171 
         TNF-α X 
Hippocampal 
Volume 
P = 0.024; 
β = -.172 
R2 change = 0.029 
P = 0.027; 
β = -.169 
R2 change = 0.028 
P = 0.033; 
β = -.163 
R2 change = 0.026 
P = 0.027; 
β = -.168 
R2 change = 0.028 
Cognitively Healthy Subjects ONLY (MCI subjects excluded) N = 139 
N = 139 Global PiB Anterior Cingulate 
Gyrus Frontal Cortex Precuneus 
TNF-α P = 0.643; 
β = 0.043 
P = 0.884; 
β = 0.014 
P = 0.722; 
β = 0.033 
P = 0.411; 
β = 0.076 
Hippocampal 
Volume/ICV 
P = 0.196; 
β = -0.118 
P = 0.288; 
β = -0.097 
P = 0.178; 
β = -0.123 
P = 0.077; 
β = -0.160 
          TNF-α X 
 Hippocampal 
Volume 
P = 0.027; 
β = -.191 
R2 change = 0.036 
P = 0.040; 
β = -.178 
R2 change = 0.031 
P = 0.039; 
β = -.178 
R2 change = 0.031 
P = 0.010; 
β = -.220 
R2 change = 0.048 
Bolded values significant at p < 0.05. All models adjusting for age, gender, and years of education.  
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Figure 7. Results from simple slope analysis in the CN subsample, illustrating the linear associations between TNF-
α and global PiB retention across several conditional values of hippocampal volume. 
3.1.5  Cross-sectional results: summary: 
3.1.5.1 Cross-sectional results summary: combined sample 
173 subjects completed a blood draw, neuropsychological assessment, and PiB-PET imaging at 
baseline, including 139 CN subjects and 34 with MCI. The 3 inflammatory biomarkers were not 
associated with baseline diagnostic status. However, there was an inverse association between 
concentrations of IL-6 and continuous composite measures of global and verbal memory 
performance, while no relationship between memory performance and the remaining inflammatory 
mediators was observed.   
We also explored the independent and interactive effects of inflammatory biomarkers and 
hippocampal volume, an established biomarker of neurodegeneration, on amyloid deposition. 
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After adjusting for age, gender, and years of education, elevated levels of circulating CD14 were 
associated with greater Aβ deposition globally and in the anterior cingulate, frontal cortex, and 
mesial temporal lobe ROI’s. Linear regression models revealed no main effect of IL-6 or TNF-α 
on global PiB-PET retention, precluding secondary regional analyses. 
However, we found that hippocampal volume moderated the association between both IL-
6 and TNF-α and amyloid load, such that elevated baseline levels of each inflammatory marker 
were associated with greater global amyloid burden specifically among those with greater 
hippocampal atrophy. Secondary analyses on regional amyloid deposition revealed that this 
synergistic relationship was also apparent in the anterior cingulate gyrus, frontal cortex, and 
precuneus. Notably, for both IL-6 and TNF-α, interaction terms largely withstood adjustment for 
demographic factors, as well as history of heart disease, hypertension, diabetes, self-reported 
depressive symptoms, white matter hyperintensities, APOE ε4 carrier status, and time from blood 
draw to PiB-PET acquisition. In fact, aside from APOE, which has a well-established relationship 
with amyloid burden, and depressive symptoms, interaction terms were the strongest predictors of 
PiB retention in hierarchical models. Interaction effects in the occipital lobe and sensory motor 
cortex did not survive correction for multiple comparisons, and the main effects of CD14 were 
attenuated after controlling for the aforementioned covariates.  
3.1.5.2 Cross-sectional results summary: cognitively healthy subsample  
In order to restrict our analyses to those that may be in the preclinical phase of AD, we also 
explored these relationships exclusively among subjects considered cognitively healthy at baseline 
(N = 139). In contrast to the null results observed in the combined baseline sample of 173 
participants, there was a negative association between TNF-α and verbal memory performance. 
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Similarly, after holding demographic factors constant, lower circulating levels of IL-6 were 
associated with better performance on composite measures of global and verbal memory.  
With respect to amyloid pathology, excluding the 34 subjects diagnosed with MCI 
diminished many of the main effects of CD14 observed in the full combined sample. While the 
relationship between CD14 and PiB retention in the anterior cingulate gyrus persisted, associations 
with global amyloid load and regional tracer uptake in the frontal cortex and mesial temporal lobe 
were no longer significant. Conversely, consistent with the findings in the combined sample, 
neither TNF-α nor IL-6 were independently associated with global amyloid deposition. There was 
also no main effect of hippocampal volume on cortical amyloid load. However, moderation models 
revealed that the relationship between both biomarkers and amyloid pathology varied as a function 
of hippocampal degeneration. Specifically, among individuals with greater hippocampal atrophy, 
elevated peripheral concentrations of TNF-α were predictive of higher PiB retention globally and 
in several regions of interest, including the anterior cingulate gyrus, frontal cortex, and precuneus. 
Notably, these interaction effects persisted after further adjustment for history of heart disease, 
diabetes, hypertension, white matter lesions, depressive symptoms, and time from blood draw to 
imaging. Adding APOE status to the model weakened interaction effects in the anterior cingulate 
gyrus and frontal cortex, resulting in trending associations for both ROIs. Hippocampal volume 
also moderated the association between IL-6 and PiB retention globally and in the precuneus, even 
after adjustment for demographic factors, cardiovascular risk factors, depression, and APOE 
status. Interaction terms were trending for the anterior cingulate gyrus, and reached significance 
in the frontal cortex ROI in conservatively adjusted models. 
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3.2 LONGITUDINAL RESULTS 
3.2.1  Subject characteristics 
Of the 173 participants that had neuropsychological, neuroimaging, and plasma data at baseline, 
90 participants completed follow-up assessments 2 years later. The average age of the 90 
participants included in the longitudinal analyses was 85.40 (SD = 2.929), with ages ranging from 
82-95 at baseline. Women comprised 41.1% of the sample (N = 37), all but 4 subjects were 
Caucasian (95.6), and participants had an average of 14.78 years of education (SD = 2.77). Forty-
nine subjects were categorized as Aβ- at baseline (54.4%), and 41 (45.6%) were considered Aβ+.  
Fifteen participants were diagnosed with MCI at baseline (16.7%), including 6 with amnestic MCI 
and 9 with non-amnestic MCI. Of the full sample, 13 subjects (15.3%) were carriers of the APOE 
ε4 genotype. Of the 75 participants that were cognitively healthy at baseline, 20 received a 
diagnosis of MCI at follow-up. According to a series of Chi-squared and two-tailed t-tests, the 83 
subjects that did not undergo neuroimaging at T2 did not differ from the 90 participants that 
returned for follow-up in terms of age, education, and concentrations of inflammatory biomarkers. 
There was a significant group difference in global and regional PiB retention, such that participants 
that did not return for follow-up, on average, had higher levels of baseline amyloid deposition 
relative to those included in the longitudinal sample.   
Among the 90 subjects included in the longitudinal sample, the 15 subjects with MCI did 
not differ from the 75 CN subjects in terms of gender and APOE ε4 distributions, age, years of 
education, or self-reported depressive symptoms. Those with MCI, on average, had significantly 
lower MMSE scores than the 75 CN subjects, although that is to be expected (t = 3.17; p = 0.032). 
Two-tailed bivariate correlations demonstrated a moderate correlation between TNF-α and CD14 
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in the full sample (r = 0.214, p = 0.043), but not IL-6 (r = 0.092; p = 0.0388). CD14 was 
significantly correlated with IL-6 (r = 0.223; p = 0.035). Table 9 includes descriptive 
characteristics for the combined longitudinal sample and the CN and MCI subsets.  
 
Table 9. Descriptive statistics for combined T1-T2 longitudinal sample and CN and MCI subsamples. 
 Combined Sample CN Subsample MCI 
 N = 90 N = 75 N = 15 
 % (N) or M (SD) % (N) or M (SD) % (N) or M (SD) 
Age 85.4 (2.93) 85.31 (2.98) 85.87 (2.7) 
Gender, % F (N) 41.1 (37) 45.3 (34) 20 (3) 
Education 14.78 (2.77) 14.99 (2.77) 13.73 (2.63) 
ApoE, % (N) 14.4 (13) 17.3 (13) 93.3 (14) 
Hx Heart Disease, % (N) 18.9 (17) 14.7 (11) 40 (6) 
Diabetes, % (N) 5.6 (5) 4 (3) 13.3 (2) 
Hypertension, % (N) 27.8 (25) 25.3 (19) 40 (6) 
MCI, % (N) 16.7 (15) -- -- 
MMSE 27.85 (1.93) 28.13 (1.65) 26.43 (2.59) 
CD14 1374.64 (286.78) 1380.92 (279.78) 1343.21 (328.31) 
TNF-α 3796.11 (960.14) 3716.30 (924.33) 4195.18 (1067.56) 
IL-6 2.76 (1.99) 2.66 (1.76) 3.27 (2.94) 
Weeks from blood 
draw to imaging 
180.89 (36.58); 
range 125 - 423 
180.3 (38); 
range 125 - 423 
185.2 (21.72); 
range 146 - 214 
T1 PiB+, % (N) 45.6 (41) 40 (30) 73.3 (11) 
T2 PiB+, % (N) 58.9 (53) 54.7 (41) 80 (12) 
CVLT Immediate 45.89 (11.39) 47.79 (10.90) 36.4 (9.02) 
CVLT Delay 8.92 (3.60) 9.57 (3.29) 5.67 (3.42) 
Rey-O Immediate 16.79 (3.56) 17.23 (3.53) 14.6 (2.83) 
 
3.2.2  Longitudinal relationships between inflammatory biomarkers, cognitive diagnosis, 
and memory performance 
3.2.2.1 Combined sample 
Hierarchical logistic regression models were employed to evaluate the association between 
baseline inflammatory biomarkers and diagnostic status at two-year follow-up. Of the 90 subjects 
that completed a neuropsychological assessment and neuroimaging at both time points, 32 met 
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criteria for MCI and 58 subjects remained cognitively normal at follow-up. After controlling for 
other risk factors associated with cognitive decline, including age, gender, and years of education, 
those with elevated baseline concentrations of IL-6 had a higher risk of having a diagnosis of MCI 
at 24 months (OR (95% CI) = 1.81 (1.08; 3.02), p = 0.024). TNF-α was not significantly associated 
with diagnostic status (OR (95%) = 1.29 (0.72; 2.31), p = 0.40), and CD14 was trending but non-
significant (OR (95% CI) = 1.74 (0.96; 3.14), p  = 0.068). 
Linear regression models were also employed to evaluate the association between 
inflammatory biomarkers and longitudinal memory performance. Dependent variables were 
unstandardized residuals, which reflected change in memory composite scores between the two 
time points, holding baseline performance constant. Elevated concentrations of TNF-α predicted 
a subsequent decrease in performance on measures of global memory (β = 0.264; p = 0.023; R2 
change = 0.059) and verbal memory (β = 0.235; p = 0.041; R2 change = 0.047), but not visuospatial 
memory. There were no statistically significant associations between baseline CD14 or IL-6 and 
longitudinal change in memory performance (all p > 0.05).  
3.2.2.2 CN subsample 
To investigate whether inflammatory biomarkers predicted progression from CN to MCI at follow-
up, binary logistic regression analyses were performed. Of the 75 subjects that were cognitively 
healthy at baseline, 20 met diagnostic criteria for MCI at the 24-month follow-up. IL-6 predicted 
subsequent cognitive status at 24 months, such that the risk of diagnostic conversion over 2 years 
was greater among those with elevated concentrations of IL-6 at baseline (OR (95% CI) = 1.86 
(1.03; 3.31); p = 0.039). CD14 and TNF-α did not predict change in cognitive status at follow-up. 
Regarding continuous composite measures of memory performance, none of the individual 
biomarkers predicted change in memory performance over the course of two years (all p > 0.05). 
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Associations between CD14 and global memory performance were trending but non-significant 
(B = .00; β = 0.219; CI = 0; 0; p = 0.094; R2 = 0.039). Similarly, the association between TNF-α 
and change in delayed performance on the CVLT was trending but no longer significantly different 
from zero in the CN subsample (B = .001; β = 0.249; CI = 0; .001; p = 0.055; R2 = 0.051).  
3.2.3  Longitudinal associations between inflammatory biomarkers, hippocampal volume, 
and Aβ deposition 
3.2.3.1 Combined sample   
Multiple linear regression models were conducted to explore associations between inflammatory 
biomarkers and change in fibrillar amyloid deposition between the two consecutive scans, while 
adjusting for age, gender, and education level. Dependent variables were residualized change 
estimates of global and regional PiB retention, and independent variables of interest were 
inflammatory biomarkers, hippocampal volume, and their interaction products. There were no 
associations between any of the 3 inflammatory biomarkers on longitudinal change in global or 
regional amyloid deposition (all p > 0.05). The interaction between each biomarker and baseline 
hippocampal volume did not predict change in global or regional PiB retention in the combined 
sample.  
3.2.3.2 CN subsample 
While IL-6 was not associated with subsequent Aβ accumulation in the combined sample, 
restricting our analyses to the 75 subjects deemed CN at baseline revealed a main effect of IL-6 
on longitudinal change in PiB retention over 24 months. Specifically, elevated baseline 
concentrations of IL-6 predicted greater regional amyloid accumulation over 2 years in the anterior 
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cingulate gyrus  (β = .272; p = 0.023; R2 change = 0.080) and precuneus (β = .243; p = 0.041; R2 
change = 0.057). The spatial specificity of these relationships was probed further using hand-drawn 
ROI’s, which demonstrated associations between elevated IL-6 and increased PiB retention in the 
dorsal precuneus (β = .324; p = 0.006; R2 change = 0.103) and the superior (β = .236; p = 0.047; 
R2 change = 0.058) and pregenual subregions (β = .284; p = 0.017; R2 change = 0.10) of the anterior 
cingulate gyrus (see Table 10). IL-6 did not predict longitudinal change in global amyloid 
deposition (β = 0.158; p = 0.190; R2 change = 0.028). Results remained when using an alternative 
change estimation approach, in which Aβ deposition at T2 served as the dependent variable for 
each ROI, holding constant PiB retention at T1. The direct effects of IL-6 on change in regional 
Aβ accumulation also withstood adjustment for hypertension, depressive symptoms, and white 
matter hyperintensities at T2. Aside from the superior anterior cingulate ROI, these associations 
also survived correction for the duration of time between blood draw to follow-up imaging (mean 
weeks (SD) = 180.3 (38); range = 125 – 423). After adjusting for all of the aforementioned 
covariates in hierarchical models, IL-6 accounted for 7.5-12.5% of the variance in change in 
regional PiB retention across these ROI’s (coefficients included in Table 10). Significance was 
attenuated in anterior cingulate ROI’s after controlling for history of heart disease and ApoE ε4 
status (Note: n = 69 in conservatively adjusted models). Diabetes was not included as a nuisance 
variable given the small number of subjects in the longitudinal subsample (N = 3) with diabetes at 
baseline. Neither TNF-α nor CD14 predicted change in global or regional PiB uptake in the 
cognitively healthy subsample. For each of the three biomarkers, interaction terms did not reach 
statistical significance. 
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Table 10. Parameter estimates from conservatively adjusted hierarchical linear regression models evaluating 
associations between IL-6 concentrations and change in amyloid deposition in ROIs. 
  Anterior Cingulate Gyrus  Posterior Anterior Cingulate Gyrus 
  N = 65  N = 65 
  β P-value R2  change  β P-value R2 change 
Age -0.011 0.387   -0.044 0.756  
Gender 0.045 0.525   0.049 0.727  
Education -0.016 0.212   -0.089 0.516  
Blood draw to  
imaging duration 0.001 0.311  
 
0.161 0.265  
Hypertension  0.03 0.71   0.096 0.503  
WMH -0.001 0.969   -0.06 0.688  
CES-D 0.004 0.591   0.079 0.562  
Hippocampal  
Volume -0.239 0.652 0.072 
 -0.148 0.28 0.072 
IL-6 0.319 0.019* 0.089  0.32 0.016* 0.093 
              Precuneus                  Upper Precuneus 
 β P-value R2  change  β P-value R2  change 
Age -0.279 0.044   -0.227 0.106  
Gender 0.057 0.668   -0.006 0.967  
Education -0.041 0.755   -0.051 0.702  
Blood draw to  
imaging duration 0.258 0.063  
 0.252 0.075  
Hypertension  0.003 0.982   -0.026 0.849  
WMH 0.1 0.481   0.134 0.354  
CES-D -0.036 0.783   -0.099 0.455  
Hippocampal  
Volume 0.083 0.525 0.154 
 0.024 0.859 0.124 
IL-6 0.286 0.025* 0.075  0.371 0.004* 0.125 
* Significant at p < 0.05. 
Note: Hippocampal volume was included with IL-6 as a predictor variable in moderation models, however, given 
the main effects of IL-6 the models were re-run to isolate the amount of variance explained by IL-6 above and 
beyond all other variables. 
 
3.2.4  Longitudinal summary 
3.2.4.1 Longitudinal summary: combined sample 
Of the 173 participants that completed baseline PiB-PET imaging and neuropsychological 
assessments, 90 older adults underwent repeated assessments 24 months later, including 75 
subjects that were CN at T1 and 15 that met diagnostic criteria for MCI. This prospective data was 
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used to evaluate associations between baseline concentrations of circulating peripheral 
inflammatory biomarkers and longitudinal changes in cognition and amyloid pathology. After 
accounting for demographic factors, subjects with elevated baseline concentrations of IL-6 were 
more likely to carry a diagnosis of MCI at the 24-month follow-up. Neither TNF-α nor CD14 were 
predictive of diagnostic status. Linear models including continuous estimates of memory 
performance revealed that elevated levels of circulating TNF-α predicted worse longitudinal 
performance on a composite measure of global memory. Probing this relationship using task-
specific composites revealed that this was largely driven by an association between higher baseline 
TNF-α and subsequent declines in verbal memory performance. Despite the relationship between 
IL-6 and diagnostic status, this biomarker did not predict change in memory performance.  
Linear models investigating the association between inflammatory biomarkers and 
prospective Aβ accumulation revealed no significant direct effects of inflammatory mediators on 
change in global or regional amyloid deposition over two years. In contrast to the cross-sectional 
findings using the combined baseline sample (N = 173), baseline hippocampal volume did not 
moderate the relationship between inflammatory markers and longitudinal amyloid accumulation. 
3.2.4.2 Longitudinal summary: CN subsample 
Among the 75 subjects that were cognitively healthy at baseline, logistic regression models 
revealed that elevated concentrations of IL-6 at T1 conferred a higher risk of conversion to MCI at 
24-months. There was not a significant relationship between CD14 or TNF-α and subsequent 
diagnostic conversion. TNF-α no longer predicted change in memory performance after excluding 
the 15 subjects with MCI, and associations between CD14 and IL-6 and continuous measures of 
memory performance remained non-significant.  
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In contrast to the null findings observed in the combined sample, restricting the analyses 
to subjects that were cognitively healthy at baseline revealed significant positive associations 
between high baseline concentrations of IL-6 and longitudinal Aβ accumulation over the course 
of two years. Exploration of hand-drawn ROIs revealed these associations to be regionally specific, 
such that IL-6 predicted increased PiB retention in the precuneus (globally and specifically in the 
upper precuneus) and the anterior cingulate gyrus (including both the pregenual and superior 
anterior cingulate regions). Adding IL-6 to models adjusting for demographic characteristics 
accounted for an additional 5.7-10.3% of the variance in progression of amyloid pathology over 
24 months. There was no association with change in global PiB retention, nor was there an 
interaction between baseline hippocampal volume and IL-6. However, IL-6 remained a significant 
independent predictor of change in amyloid deposition after controlling for hypertension, white 
matter hyperintensities, and self-reported depressive symptoms, but attenuated in all ROI’s aside 
from the upper precuneus after additional adjustment for history of heart disease and APOE ε4 
genotype. Taken together, higher concentrations of circulating IL-6 predicted subsequent 
conversion to MCI and increased longitudinal accumulation of Aβ pathology in regions susceptible 
to early amyloid deposition exclusively among participants considered cognitively healthy at 
baseline. There were no direct effects of CD14 or TNF-α on change in amyloid burden, and 
interaction terms failed to reach statistical significance.  
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4.0 DISCUSSION 
4.1 SUMMARY 
Individuals harbor Aβ plaques for 10-20 years before the symptoms of AD become clinically 
apparent. In order to delay or even prevent AD, the greatest chance for success likely involves 
intervening early in this pathogenic process, well before the onset of cognitive symptoms. 
Offsetting this disease trajectory requires an enhanced understanding of the molecular processes 
that initiate and exacerbate Aβ prior to symptom manifestation. Abundant evidence from rodent 
and primate models demonstrates the central contribution of pro-inflammatory processes to the 
generation and progression of neurotoxic Aβ.  Despite this, remarkably little translational work 
has been conducted in humans. The present study addressed substantial gaps in the literature by 
exploring the association between peripheral inflammatory markers, cognition, and amyloid 
pathology in a sample of non-demented elderly adults. Using the NIA-AA framework of 
preclinical AD, this study also aimed to evaluate potential disease-state-dependent differences in 
these relationships specifically among CN older adults. Finally, for the first time in humans, we 
determined whether peripheral inflammatory biomarkers predicted the longitudinal progression of 
amyloid pathology during this critical preclinical phase. Understanding how these biomarkers are 
associated with AD-related pathology prior to the onset of cognitive symptoms could help identify 
individuals at high risk for impending cognitive decline, improve timely diagnoses of AD, and 
facilitate earlier intervention. 
In a sample of 173 non-demented elderly adults, we found that indicators of chronic, 
systemic inflammation were associated with and predictive of the progression of one of the 
 95 
primary neuropathologic features of AD. Specifically, higher circulating concentrations of two 
peripheral pro-inflammatory biomarkers, IL-6 and TNF-α, were associated with elevated global 
Aβ deposition specifically among those that also exhibited greater hippocampal atrophy. 
Secondary ROI analyses demonstrated that interaction effects between inflammatory biomarkers 
and hippocampal volume were specific to PiB uptake in regions susceptible to early Aβ 
accumulation, including the precuneus, anterior cingulate gyrus, and prefrontal cortex. Both TNF-
α and IL-6 were also independently associated with poorer verbal memory performance in CN 
older adults. Finally, longitudinal analyses revealed that elevated baseline concentrations of IL-6 
predicted conversion to MCI and greater regional amyloid accumulation over the course of 2 years.  
4.2 CROSS-SECTIONAL FINDINGS 
4.2.1  Inflammatory biomarkers and cognitive performance 
Extant studies in humans have largely evaluated the relationship between inflammation and AD 
by comparing concentrations of inflammatory biomarkers between individuals with and without 
detectable cognitive impairment. This includes epidemiological studies that demonstrate 
differences in cytokine expression between cognitively healthy older adults and those with 
advanced AD (Brosseron et al., 2014). However, the relationship between inflammatory markers 
and subtle cognitive changes prior to dementia onset has not been well characterized (Brosseron, 
Krauthausen, Kummer, & Heneka, 2014; Saleem, Herrmann, Swardfager, Eisen, & Lanctot, 
2015). To decompose this, we examined the relationship between peripheral biomarkers and 
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cognition in a large sample of non-demented older adults (MCI & CN), and assessed whether 
associations were specific to, or observed exclusively in, cognitively intact older adults.  
We found that elevated levels of IL-6, an indicator of chronic, systemic inflammation, were 
associated with poorer global and verbal memory performance in the full sample. Moreover, the 
relationship between IL-6 and verbal memory persisted after restricting the analysis to CN 
participants. This is consistent with findings from Marsland et al., (2015) showing that higher 
concentrations of circulating IL-6 were associated with poorer performance on measures of spatial 
reasoning, learning, memory, and executive function in a sample of middle-aged adults (Marsland 
et al., 2015). However, although studies in CN older adults demonstrate associations between IL-
6, executive function, and processing speed, they have failed to find links with immediate or 
delayed verbal memory performance (Heringa et al., 2014; Palta et al., 2014; Stenfors, Jonsdottir, 
Hanson, & Theorell, 2017; Tegeler et al., 2016). The discrepancies between the present findings 
and prior work in older adult populations may be due to variations in the verbal memory measures 
used, small sample sizes, and the age distribution of study populations. The age range of the 
GEMS-PGG sample is more advanced than those included in the aforementioned studies. While 
chronic, low-grade inflammation may initially be associated with delayed processing speed and 
executive dysfunction in older adulthood, it’s possible that these relationships become more 
broadly distributed and encompass multiple cognitive domains with advancing age. The 
availability of processing speed and executive function measures in this dataset offers 
opportunities for further evaluation of the domain-specificity of this relationship in this sample. 
Interestingly, associations between TNF-α and verbal memory performance surfaced only 
after excluding subjects with MCI. The specificity of this relationship in the CN subsample 
suggests potential disease-state-dependent differences in biomarker expression, such that elevated 
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TNF-α may be associated with subtle cognitive changes prior to the onset of clinically detectable 
cognitive symptoms. This could account for some of the discrepant findings across studies 
evaluating differences in TNF-α levels between CN, MCI, and early AD populations. For instance, 
a recent meta-analysis found that 2 studies reported up-regulation of TNF-α in the plasma or CSF 
of patients with MCI relative to controls, while 3 showed no group differences and one reported 
downregulation of TNF-α among those with MCI (Brosseron et al., 2014). It is becoming 
increasingly clear that these inflammatory processes become relevant much earlier in the disease 
course, well before symptom manifestation. Accordingly, those in the preclinical phase may 
already be expressing elevated inflammatory levels without exhibiting outward cognitive deficits, 
thereby diluting potential group differences in biomarker expression between CN and MCI 
populations.  
4.2.2  Inflammatory biomarkers, neurodegeneration, and amyloid pathology 
4.2.2.1 Disease state-dependent differences in biomarker expression 
Pro-inflammatory states are now widely recognized as naturally occurring and predominant 
features of nearly all neurodegenerative diseases, including AD. Nevertheless, how these 
inflammatory processes impact the pathogenesis of AD, and when they first start to take effect, is 
poorly understood. We aimed not only to characterize the relationship between inflammatory 
biomarkers and amyloid pathology in non-demented subjects, but also to explore how these 
relationships may vary across different stages along the preclinical continuum of AD. According 
to the NIA-AA, amyloid deposition is the first detectable change in the preclinical cascade, 
followed subsequently by synaptic dysfunction, hippocampal atrophy, and the formation of 
neurofibrillary tangles (phase 2), which develop prior to the onset of cognitive symptoms (Counts 
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et al., 2016; Jack et al., 2011; R. Sperling et al., 2014; Vlassenko et al., 2012). In order to 
distinguish individuals potentially representing more advanced stages of preclinical disease 
progression, hippocampal volume was used in the present study as a proxy for neurodegeneration. 
Consistent with our hypothesis, the association between biomarker expression and Aβ 
varied as a function of hippocampal volume, such that higher levels of IL-6 and TNF-α were each 
predictive of elevated amyloid deposition specifically among those exhibiting greater 
neurodegeneration. In other words, while neither hippocampal volume nor TNF-α or IL-6 were 
independently associated with PiB uptake, their combined presence was associated with greater 
global amyloid burden. Simple slope analyses revealed that among subjects with average to high 
hippocampal volume (e.g., displaying minimal hippocampal degeneration), amyloid deposition 
remained stable across varying levels of cytokine expression. Conversely, among individuals 
exhibiting the most hippocampal atrophy, low levels of TNF-α and IL-6 were associated with 
reduced amyloid load, whereas elevated concentrations predicted greater amyloid burden. These 
findings were observed in the full sample and persisted after restricting our analyses to the CN 
subsample, indicating that the subjects with MCI did not drive these significant interaction effects.  
The process of microglial priming following early Aβ aggregation lends mechanistic 
support to the interaction effects observed in the present study. While the cumulative impact of 
inflammatory processes appears detrimental, the pro-inflammatory cascade may, temporarily, be 
neuroprotective. Indeed, rodent models indicate that microglial activation initially helps to reduce 
Aβ pathology by increasing phagocytosis, promoting the breakdown and clearance of neurotoxic 
Aβ species, and stimulating the release of protective trophic factors (Fan et al., 2015; Heneka et 
al., 2015; Ramesh et al., 2013; W.-Y. Wang et al., 2015). However, chronic or prolonged exposure 
to amyloid aggregates results in microglial priming, causing these highly plastic immune cells to 
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become highly sensitized to further activation. This results in a sustained, pro-inflammatory 
environment characterized by the overexpression of chemokines and cytokines, including IL-6 and 
TNF-α. In the present study, we attempted to approximate or estimate this phenotypic shift by 
identifying those exhibiting downstream neurodegenerative changes in the form of hippocampal 
atrophy. Participants with greater hippocampal atrophy may be further along the preclinical 
continuum, suggesting prolonged exposure of brain-resident immune cells to neurotoxic Aβ 
species and, potentially, an enhanced sensitivity to peripheral pro-inflammatory signaling. 
Although there are numerous pathways by which this pro-inflammatory cascade 
potentiates the generation of Aβ species, of particular relevance to the present study are animal 
models elucidating the direct effects of IL-6 and TNF-α on Aβ. For example, over-expression of 
both IL-6 and TNF-α up-regulate the aberrant cleavage of APP (Calsolaro & Edison, 2016; Walters 
et al., 2016), which is necessary for Aβ generation. TNF-α signaling also increases the expression 
of β-secretase and the activity of γ-secretase (Calsolaro & Edison, 2016; Sastre et al., 2003; Walters 
et al., 2016), the cleaving enzymes that produce neurotoxic Aβ (Heppner et al., 2015). Notably, 
introducing anti-inflammatory agents that target these pathways lowers Aβ generation and β-
secretase activity, abolishes Aβ-related cellular toxicity, and improves learning and memory 
deficits in rodent and primate models (Decourt et al., 2016; He et al., 2013); (Shamim & 
Laskowski, 2017; Tweedie et al., 2012). Both TNF-α and IL-6 exacerbate the pro-inflammatory 
drive in the CNS by enabling further activation of primed microglial cells (Calsolaro & Edison, 
2016; W.-Y. Wang et al., 2015).  
While not specific to the preclinical phase, other work in humans supports the possibility 
of disease-state-dependent differences in inflammatory profiles. For instance, in a cross-sectional 
study by Parbo and colleagues (2018), 6 subjects with AD and 20 with MCI underwent 
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inflammation (11C-(R)-PK11195), amyloid (11C-PiB), and tau (18F-flortaucipir) PET imaging. The 
authors observed correlations between microglial activation and amyloid deposition in individuals 
with amnestic MCI, but not those diagnosed with AD. Furthermore, they found elevated microglial 
activation in PiB+ MCI cases where tau signals were low. The authors concluded that the 
correspondence between inflammatory processes and Aβ deposition may be stronger prior to AD 
onset. They also noted that immune cell activation may precede tau deposition, and thus represent 
an important process that occurs earlier in the disease course (Parbo et al., 2018). Similarly, 
Yasuno et al., (2012) found elevated microglial tracer uptake among subjects with MCI and AD 
relative to controls, but no difference in microglial activation between those with MCI and AD 
(Yasuno et al., 2012). The absence of group differences among those with MCI and AD suggests 
that particular inflammatory processes may be elevated earlier in the disease course. There are 
several implications of these findings, including the possibility that there may be critical periods 
when amyloid lowering therapies targeting inflammatory processes may be most efficacious.  
One major caveat of this interpretation is that hippocampal degeneration in older adulthood 
is not specific to AD. Hippocampal atrophy can develop in the context of many other 
neuropathological conditions, including Lewy body disease, medial temporal tauopathy without 
Aβ, and cerebrovascular disease (Jack et al., 2014). Sometimes termed suspected non-Alzheimer 
pathophysiology (SNAP), this reflects populations that exhibit abnormal imaging biomarker(s) but 
do not fit into the NIA-AA framework due to an absence of elevated Aβ. A seminal study found 
that 23% of participants with biomarker abnormalities aligning with AD-related pathology (e.g., 
hippocampal degeneration, hypometabolism) fit into the SNAP group (Jack et al., 2014), which is 
consistent with more recent estimates (Morimono et al., 2016). This is an important limitation to 
the cross-sectional interpretation, as it cannot be assumed that reduced hippocampal volume is 
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indicative of an underlying or ongoing AD process (or even progression along the preclinical AD 
continuum). It is possible that those who exhibit greater hippocampal degeneration are generally 
more sensitive to peripheral influences, although this may not be due to an underlying AD process.  
To try to address this limitation, we conducted a post hoc analysis exploring the interaction 
between inflammatory biomarkers and hippocampal volume exclusively among the 93 subjects 
that exhibited elevated global amyloid deposition based on conventional dichotomous standards. 
Therefore, greater hippocampal atrophy among these PiB+ participants may better reflect the latter 
stages of neuropathological progression in preclinical AD. Notably, the interaction between IL-6 
and hippocampal volume persisted in this subsample, indicating that among subjects meeting 
conventional thresholds of PiB positivity, elevated concentrations of IL-6 were associated with 
greater global amyloid burden among those also displaying hippocampal atrophy. Notably, the 
effect size of the interaction term nearly doubled after restricting the analysis to PiB+ subjects.  
4.2.2.2 Direct associations between inflammatory biomarkers, hippocampal atrophy, and 
Aβ deposition 
Although the bulk of the cross-sectional findings involved TNF-α and IL-6, main effects models 
revealed a direct association between elevated soluble CD14 concentrations and greater global 
amyloid deposition at baseline. CD14 is a surface antigen that is abundantly expressed on 
monocytes and macrophages in the periphery. CD14 detects invading pathogens and in particular 
binds to lipopolysaccharide (Zhan et al., 2018), interacting with toll-like receptors to facilitate 
phagocytosis and induce the production of several cytokines including IL-1, TNF-α, and IL-6 
(Leveque, Jeune, Jouneau et al., 2017). Relative to TNF-α and IL-6, CD14 has been understudied 
in humans and rodent models of AD. Therefore, the precise mechanisms linking this cell surface 
receptor to amyloid pathology remain speculative. It is notable that the direct association between 
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CD14 and amyloid load did not survive adjustment for cardiovascular risk factors in the present 
study. Furthermore, two-tailed T tests also showed that CD14 levels were significantly higher in 
hypertensive relative to normotensive subjects, with trending group differences among those 
with/without a history of cardiovascular disease. Statin treatment among those with hypertension 
reduces soluble CD14 expression (Frey et al., 2007). CD14 may also be involved in low-density 
lipoprotein binding and has been shown to promote low-density lipoprotein-induced cytokine 
release (Estruch, Bancells, Beloki et al., 2013). Taken together, the cross-sectional associations 
with amyloid load observed here may be linked to the relationship between CD14 and 
cardiovascular risk factors. 
Main effects models also revealed that hippocampal atrophy did not independently predict 
global PiB retention. The absence of a main effect of hippocampal volume on Aβ deposition found 
here is consistent with numerous prospective and cross-sectional studies demonstrating no 
association between amyloid load and hippocampal atrophy at the earliest stages of disease onset 
(Jack et al., 2014; Vos et al., 2013 Achenbrenner et al., 2018). In fact, these findings have been 
used to inform and confirm the NIA-AA framework of amyloid pathogenesis as a biologically 
distinct process that is initiated prior to AD-related neurodegeneration. 
4.2.2.3 Regionally specific associations between inflammation, hippocampal volume, and 
amyloid deposition 
Of the circumscribed body of literature that has explored the relationship between peripheral 
inflammation and amyloid pathology, most has been conducted using CSF-derived measures of 
Aβ. This is the second study, to our knowledge, to investigate the associations between peripheral 
pro-inflammatory biomarkers and amyloid pathology measured in the brain, and the first to explore 
the regional specificity of these relationships. We found that both TNF-α and IL-6 were associated 
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with focal Aβ deposition in the anterior cingulate gyrus, frontal cortex, and precuneus ROIs. 
Notably, hierarchical staging models of preclinical Aβ progression indicate that these regions are 
associated with deposition patterns that occur during the earliest stages of amyloidosis (Cho et al., 
2016; Vlassenko et al., 2012; Grothe et al., 2017; Villeneuve et al., 2015). Interaction effects were 
also apparent in the mesial temporal lobe and occipital structures, although these did not meet 
multiple comparison correction thresholds. These trends align with extant studies in older adults 
showing regionally distinct relationships between systemic inflammation and brain structure and 
function. For instance, in a sample of cognitively healthy older adults, Warren and colleagues 
(2018) found that elevated levels of IL-6 predicted greater declines in cerebral blood flow 
specifically in the orbitofrontal cortex and hippocampal region over a 5-year period (Warren et al., 
2018). In a middle-aged sample, Marsland et al., (2017) found that IL-6 was associated with 
alterations in functional connectivity in the anterior cingulate and dorsal medial prefrontal regions 
of the Default Mode Network (Marsland et al., 2017). Dev and colleagues (2017) also found that 
elevated IL-6 predicted reduced BOLD activation in the parietal cortex and middle frontal gyrus 
during a working memory task (Dev et al., 2017). Similarly, elevated TNF-α levels have been 
linked to reduced gray matter volume in the medial prefrontal cortex and hippocampus in middle-
aged (Marsland et al., 2015) and older adults (Zhang et al., 2016), as well as decreased functional 
connectivity in the default mode network (Magalhães et al., 2018). Taken together, these studies 
provide evidence of the relationship between systemic inflammation and variations in cerebral 
blood flow, neural recruitment, and functional connectivity in the prefrontal, mesial temporal, and 
parietal cortices. Along with corroborating the regional specificity observed in the present work, 
these studies also illustrate the sensitivity of the aging brain to peripheral inflammatory states. 
 104 
4.3 LONGITUDINAL FINDINGS 
4.3.1  Systemic inflammation and AD: longitudinal relationships between peripheral 
biomarkers, cognition, and amyloid pathology 
The exploration of the role of peripheral inflammatory biomarkers in the present study reflects an 
evolving perspective of AD pathogenesis as a systemic process. Novel perspectives of AD etiology 
have begun to consider the entire system, including the critical impact of peripheral health, on 
disease onset and progression (Eikelenboom et al., 2012; Mietelska-Porowska & Wojda, 2017; J. 
Wang, Gu, Masters, & Wang, 2017). This is exemplified by a recent review in Nature Reviews, 
Neuroscience, in which the authors state, “We propose that AD might not be solely a brain 
disorder, in the sense that systemic factors might interact with the brain to modify the AD 
process… The crucial questions to answer would be precisely how the brain and periphery 
interact with each other to affect AD progression, and whether interventions that target systemic 
factors can modulate the pathogenesis or development of AD” (Wang et al., 2017). Identifying 
systemic factors that contribute to the pathogenesis of AD could offer a host of new therapeutic 
opportunities targeting peripheral health to alter disease risk (Wang et al., 2017). 
 Consistent with this notion, results from the present study reveal relationships between 
estimates of chronic inflammation measured in the systemic circulation and AD-related pathology 
in the brain. Mechanistically, this is supported by work showing that primed microglia exhibit an 
exaggerated response to both central and peripheral inflammatory signaling. While it was once 
believed that inflammatory cells in the circulation could not invade the CNS, it is now understood 
that complex, dynamic, and elaborate pathways exist that allow for peripheral immune cells to 
infiltrate the CNS and influence inflammatory processes in the brain (see Capuron and Miller, 
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2011, for review). In the context of AD, overexpression of pro-inflammatory cytokines following 
initial Aβ deposition functionally alters the permeability of the BBB, reducing the integrity of this 
critical gating system and enabling the infiltration of peripheral immune cells into the brain 
((Bradburn et al., 2018; Calsolaro & Edison, 2016; Heppner et al., 2015; MacPherson et al., 2017; 
W.-Y. Wang et al., 2015). Indeed, acute systemic events restricted to the periphery, such as induced 
osteoarthritis, increase pro-inflammatory signaling in the brain, as well as Aβ aggregation and 
deposition in rodents (Kyrkanides et al., 2011). Moreover, introducing inhibitors of these pro-
inflammatory pathways into the systemic circulation reduces microglial activation and decreases 
the deposition of Aβ peptides (MacPherson et al., 2017). Thus, the early deposition of Aβ alters 
local immune cell signaling, permitting pro-inflammatory mediators that proliferate in a state of 
chronic inflammation to have additive or even distinct neuromodulatory effects. 
This dynamic immune-brain communication in the context of AD has given rise to the 
‘second hit’ hypothesis, suggesting that those with Aβ pathology are particularly susceptible to 
subsequent inflammatory events, including those that originate in the periphery. This theory is 
supported, in part, by studies showing that acute systemic inflammatory events can result in a 
combination of symptoms known as ‘sickness behavior’ among individuals with AD. Often 
induced by infection, injury, or other immune-compromising conditions (e.g., respiratory 
infections, genitourinary infections, surgical interventions), sickness behavior reflects a 
constellation of neuropsychiatric symptoms, including anxiety, depressed mood, apathy, social 
withdrawal, listlessness and fatigue (Dantzer, O'Connor, Freund, Johnson, & Kelley, 2008; C 
Holmes, Cunningham, Zotova, Culliford, & Perry, 2011; Maes et al., 2012). In a prospective 
cohort study of 300 older adults with AD, raised serum concentrations of both TNF-α and IL-6 
predicted a 2-fold increase in the frequency of neuropsychiatric symptoms associated with sickness 
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behavior, including low mood, agitation, and anxiety (Holmes et al., 2011). Furthermore, the rate 
of cognitive decline doubled among subjects that experienced acute systemic inflammatory events 
over the 6-month follow-up period (Holmes et al., 2009). Moreover, acute illness and raised levels 
of pro-inflammatory markers increase the likelihood of delirium onset among those with AD 
(Simone & Tan, 2011). Taken together, these results demonstrate that, in this highly vulnerable 
population, more severe or acute systemic inflammatory events lead to significant alterations in 
symptom presentation and severity. This work also provides corroborating evidence of the 
mediating role of IL -6 and TNF-α in facilitating communication between the periphery and the 
brain.  
Our longitudinal results support and expand upon this work by showing that along with 
acute events, sustained, low-grade chronic inflammation may also have neural and cognitive 
consequences.  The findings in the present study further indicate that this systemic inflammatory 
state may become relevant much earlier in the disease course, leading to more subtle changes in 
cognitive function and potentiating Aβ pathogenesis. Specifically, we found that elevated IL-6 
levels predicted a regionally specific pattern of Aβ progression, including increased amyloid 
deposition in sub-regions of the anterior cingulate gyrus and precuneus. These results are 
consistent with the regionally distinct findings observed in our cross-sectional models, and reflect 
brain areas that are most vulnerable to early Aβ deposition. A critical facilitator of both the acute 
phase response and sustained inflammatory signaling, IL-6 has been implicated in numerous 
chronic inflammatory conditions including obesity, rheumatoid arthritis, and atherosclerosis. 
Relative to other signaling molecules including TNF-α, IL-6 has a longer half-life and when 
measured in the circulation is considered a reflection of systemic, low-grade inflammation (Lim 
& Marsland, 2013). While studies have shown that IL-6 predicts the subsequent risk of all-
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cause dementia (Darweesh et al., 2018), we were unable to find any previous work 
demonstrating that IL-6 predicts conversion from CN to MCI. Based on our results, it is possible 
that chronically elevated levels of IL-6 may accelerate the deposition of Aβ pathology and, 
consequently, place individuals at a higher risk of developing cognitive symptoms. 
Moderation models in the present study withstood adjustment for a host of factors known 
to contribute to Aβ pathogenesis, including APOE ε4 status, diabetes, hypertension, history of 
heart disease, white matter hyperintensities, and depression. Even longitudinal models, which 
included only half of the original sample size, survived adjustment for white matter pathology, 
depression, and hypertension, although results were trending after additional adjustment for history 
of cardiovascular disease. It has previously been suggested that systemic inflammation may be one 
causal pathway linking cardiovascular disease risk factors to amyloid deposition and AD risk. 
However, our results indicate that the influence of inflammatory factors on Aβ deposition may 
reflect a pathway that is mechanistically distinct or independent of the impacts of cardiovascular 
risk factors. This possibility is supported by epidemiological studies showing that pro-
inflammatory conditions without a cardiovascular disease component, such as osteoarthritis (Chen 
et al., 2018) and periodontitis (Teixeira et al., 2017), are also associated with increased risk of AD. 
Of note, however, the present study used binary threshold cut-offs to represent cardiovascular risk 
factors (e.g., diabetes Y/N). The range or magnitude of CVD risk factors may be better represented 
with continuous variables, which may increase the power and sensitivity to detect relationships 
between CVD risk factors and inflammatory biomarkers. 
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4.4 LIMITATIONS 
While this large, longitudinal sample of older adults is unique in many ways, certain sample 
characteristics may limit the generalizability of this study. Specifically, a survival effect is likely 
to limit interpretation, as the advanced age of this sample (mean age = 86 at baseline imaging) 
exceeds the average United States lifespan, suggesting that these subjects may be healthier and 
may have a more adaptive immune system than the general population. Further, the presence of 
Aβ pathology without corresponding clinical symptoms at this age suggests these subjects may 
contain protective factors that may not be present to a similar degree in the broader population. 
However, given that we were able to detect these results in a relatively healthy elderly sample, it’s 
likely that the magnitude of these relationships might be even larger in a general population sample 
evidencing greater cardiovascular burden and fewer protective factors. There was also a significant 
loss to follow-up between the 2009 and 2011 imaging assessments, with the sample size decreased 
by ~ 45%, which further limits interpretation. Of note, however, those that underwent 
neuroimaging once again in 2011 did not significantly differ demographically or by weight, APOE 
genotype, or cognitive status from the full baseline sample.  
In addition, inflammatory data was only taken at a single time-point and may not be 
representative of the inflammatory milieu at the time of follow-up imaging. Furthermore, the study 
sample represents a subset of subjects that had participated in a clinical trial. Therefore, blood data 
was collected at the close-out visit of the clinical trial and the first PiB scan, considered baseline 
in the present study, was completed an average of 82 weeks later. Follow-up imaging was collected 
an average of 185.2 weeks (~ 3.5 years) after initial blood draw. Although other studies have 
shown that these biomarkers have moderate to high stability over time (particularly IL-6) (Alley 
et al., 2007; Clendenen et al., 2010; Epstein et al., 2013), multiple assessments would help to 
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confirm the longitudinal validity of these findings. The lack of multiple assessments of 
inflammatory biomarkers precludes our ability to make any causal interpretations from our 
findings. However, given that we observed these relationships both cross-sectionally and 
longitudinally despite the duration between biomarker collection and neuroimaging, the magnitude 
of these associations might be even stronger if these variables were more temporally connected. 
Additionally, the use of statins and anti-inflammatory medications were not controlled for in the 
present study and may impact the reported associations.  
The present study used a TNF-α variable that reflected an average of soluble TNF-α 1 and 
2 receptor levels to minimize type 2 error. Evaluating TNF receptor levels is advantageous in 
longitudinal studies, as solube TNF-α receptors are considered to be more stable over time than 
TNF-α itself (Lai et al., 2017). However, mouse models indicate potential mechanistic differences 
between these receptors, with one exhibiting more of a neuroprotective role than the other (Delaby 
et al., 2015). Although rarely assessed in humans, one study found that both receptors 1 and 2 
predicted conversion from MCI to AD (Diniz et al., 2010), suggesting possible mechanistic 
similarities in humans. However, future work should evaluate the potentially divergent roles of 
these receptors in humans.   
Given the notably smaller sample size containing longitudinal data, we were likely 
underpowered to detect interaction effects between inflammatory mediators and hippocampal 
volume on changes in PiB retention over the follow-up periods. Furthermore, the hippocampal 
atrophy variable reflected hippocampal volume at baseline. While this was appropriate for the 
cross-sectional analysis, the rate or magnitude of hippocampal change may serve as a more 
sensitive moderator to explore change in amyloid burden over time. In addition, our moderation 
analyses may not fully capture individuals that have surpassed the initial preclinical stage of AD. 
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The presence of significant hippocampal atrophy, hypometabolism, or tauopathy correspond to the 
second phase of preclinical pathology. The latter two biomarkers were not evaluated in the present 
study and therefore, we were unable to identify individuals exhibiting these manifestations of 
preclinical AD pathology. Although one of the most commonly used tracers to identify and 
quantify Aβ plaque deposition, (PiB) is only capable of detecting insoluble fibrillar Aβ (Heppner 
et al., 2015). Other forms of Aβ aggregates (Aβ oligomers and monomers) also have pathogenic 
effects in the brain (Heppner et al., 2015), and therefore results from PET imaging may not 
completely capture the extent of Aβ pathology in the brain.  
We used continuous estimates of PIB retention to maximize power and explore 
associations that may not be detected using conventional dichotomous cut-offs. However, PiB 
positivity thresholds were originally developed, in part, to distinguish noise from clinically 
meaningful tracer binding (Grothe et al., 2017). Therefore, by using continuous measures, we may 
be uncovering differences in PiB uptake that are not pathologically significant. However, recent 
epidemiological studies provide support for the behavioral and pathogenic relevance of 
subthreshold amyloid deposition (Grothe et al., 2017, Landea et al., 2018, Leal et al., 2018). This 
work has shown that elevated Aβ concentrations in CN older adults classified as amyloid negative 
(PiB-) using standard thresholds predicts subsequent declines in cognitive performance (Landea 
et al., 2018) and greater tau deposition 4-5 years later (Leal et al., 2018). These findings underscore 
the important information that can be derived using continuous estimates of Aβ deposition, 
particularly among studies interested in the earliest phases of disease onset. 
The present study also evaluated associations between inflammatory biomarkers and 
regional PiB retention. Global indicators are often preferable because of the relatively poor spatial 
resolution of PET imaging compared to MR imaging, which may limit the precision of the ROIs 
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(Grothe et al., 2017). Alternatively, regionally specific patterns of Aβ deposition may provide 
unique information that would otherwise be eclipsed using global amyloid estimates. Indeed, 
global measures of PiB deposition do not capture the hierarchical progression of amyloid 
accumulation that takes place in the earliest phases of amyloid pathogenesis (Grothe et al., 2017; 
Jansen et al., 2018; Villeneuve et al., 2015). As a result, ROI-based approaches have recently been 
applied to elucidate potential predictors and correlates of early amyloid deposition, including gait 
speed (Nadkarni et al., 2017), genetic risk factors (Gordon et al., 2018), and obstructive sleep 
apnea (Yun et al., 2017). While we failed to find a longitudinal relationship between IL-6 and 
change in global PiB uptake in the present study, ROI analyses enabled us to identify regionally 
specific associations with frontal and parietal areas that would have been undetected using 
traditional whole brain estimates. 
4.5 FUTURE DIRECTIONS 
The pathogenesis of AD is becoming increasingly understood as a complex, multifactorial process 
that is likely to be affected by factors occurring or originating outside of the brain, including 
systemic inflammation. It is unlikely that pro-inflammatory processes represent the single 
molecular event that precipitates the initial generation and aggregation of pathological Aβ peptides 
in AD. Rather than a precursor, systemic inflammatory may act as an accelerator, hastening an 
ongoing or underlying neurodegenerative process. Consistent with this, our results suggest that 
those suffering from low-grade, chronic systemic inflammation may also have a heightened risk 
of Aβ progression and clinically significant cognitive decline.  To confirm and expand upon these 
results, additional longitudinal studies involving assessments of inflammatory biomarkers at 
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multiple time points are necessary to further elucidate the impact of systemic inflammation on the 
nature and rate of disease progression in AD. 
Evaluating correlates of Aβ deposition using a more comprehensive panel of inflammatory 
biomarkers, including chemokines, cell surface receptors, and both pro- and anti-inflammatory 
cytokines, is needed to more precisely identify protein signatures of preclinical AD. Our results 
suggest that biomarker concentrations may peak or become particularly relevant during distinct 
time points of preclinical disease development. For example, we found direct associations between 
cell-surface receptor CD14 and amyloid deposition, whereas TNF-α and IL-6 associations with 
amyloid deposition were only revealed when hippocampal atrophy was included as a moderator. 
Circulating inflammatory biomarkers can be rapidly and easily measured in clinical settings, and 
further characterization of both the cellular and temporal specificity of these relationships could 
help to nominate potential targets for early intervention.  
Findings from the present study may also inform or apply to other persisting questions 
regarding the onset and progression of AD. Although the duration of illness is variable, on average, 
individuals survive for 4 to 8 years after the initial diagnosis of AD. However, AD progresses at 
different rates among affected individuals and some may live as long as 20 years following the 
initial diagnosis, although the reasons for this variability are not well understood (Association, 
2013, 2014). Similarly, while some individuals with MCI (now known as mild neurocognitive 
disorder) go on to develop AD and other dementias, others remain stable or even reverse to 
subclinical levels of impairment. The reasons for this inter-individual variability are poorly 
understood. Peripheral health factors like systemic inflammation may contribute to this 
heterogeneity. Our results indicate that systemic inflammation predicted conversion from CN to 
MCI, as well as accelerated regional amyloid accumulation over 2 years. Similarly, a small-scale 
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longitudinal study found elevated TNF-α concentrations among subjects that progressed from MCI 
to dementia relative to those whose MCI status remained stable over the course of 12 months 
(Diniz et al., 2010). Thus, another important avenue for future work is establishing whether (and 
to what extent) the systemic inflammatory environment moderates the nature and rate of symptom 
progression across various stages of disease onset. 
There is also a limited understanding of the relationship between central (CSF) and 
peripherally derived inflammatory biomarkers. Emerging evidence indicates that systemic 
inflammatory processes may impart additive or even distinct effects on Aβ pathogenesis (Bettcher 
et al., 2018; Swardfager et al., 2010). Future work estimating inflammatory biomarkers in both the 
blood and CSF may help to distinguish central versus systemic effects of inflammatory processes 
on AD. Furthermore, along with Aβ peptides, tau pathology is a hallmark characteristic of AD. 
Transgenic models of AD in rodents have shown that inflammatory processes promote multiple 
downstream neurodegenerative changes, including tau pathology. For instance, overexpression of 
pro-inflammatory cytokines IL-1, IL6, and IL-18 has been shown to enhance the aberrant 
phosphorylation of tau proteins (Wang et al., 2015). However, similar to Aβ, translational work in 
humans is sparse, particularly regarding relationships with brain-estimated tau pathology. It’s 
possible that inflammatory pathways may be a viable target to modify both amyloid and tau 
pathogenesis, necessitating further evaluation of these relationships with tau and amyloid 
pathology across disease states. This could provide a clearer understanding of whether systemic 
management of inflammatory processes may help to prevent or slow the progression of AD-related 
pathology. 
These future directions are encompassed in a recent study protocol published in BMJ, 
which seeks to explore the pathophysiological mechanisms by which central and peripheral 
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inflammation promotes neuropathology. This year-long prospective study will involve collection 
of both central and peripheral inflammatory biomarkers, structural imaging, and PET-estimated 
amyloid deposition and tauopathy in populations with AD, progressive supranuclear palsy, 
frontotemporal dementia, Lewy body dementia, and MCI (Bevan-Jones et al., 2017). These study 
objectives not only highlight the potential scope of neuropathological change associated with 
chronic inflammation, but also illustrate the necessity of evaluating the critical role that systemic 
inflammation may play in the pathogenesis of a range of neurological conditions.  
Finally, strategies to reduce systemic inflammation may extend beyond pharmaceutical 
treatments and include behavioral interventions, such as physical activity (PA) training. 
Randomized controlled trials have demonstrated the anti-inflammatory effects of PA in older 
adults, particularly regarding measures of systemic inflammation including interleukin-6, TNF-α, 
and C-reactive protein (Manuela Crispim Nascimento et al., 2014; Monteiro-Junior et al., 2018; 
Santos et al., 2012; Sardeli et al., 2018). Notably, preliminary work indicates that greater 
engagement in PA is associated with lower levels of amyloid deposition in CN older adulthoods 
(B. M. Brown et al., 2017; Liang et al., 2010) and those with MCI (Baker et al., 2010). Although 
speculative, PA may modify Aβ deposition by 1) reducing systemic inflammatory signaling and/or 
2) altering the neuroinflammatory processes that potentiate Aβ accumulation. By modifying 
inflammatory pathways, PA may be a promising approach to reduce the development or 
progression of neurotoxic Aβ. However, the current evidence base is encumbered by small sample 
sizes and cross-sectional designs. Large, randomized-controlled exercise intervention trials in 
older adults, involving multiple assessments of amyloid deposition and biomarker expression, will 
be imperative to evaluate the potentially protective impact of PA on the pathogenesis of AD.  
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